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Characterization of Protein-Metabolite and Protein-Substrate 
Interactions of Disease Genes 
Abstract 
 
Discovery of protein-metabolite and protein-substrate interactions that can specifically 
regulate genes involved in human biology is an important pursuit, as the study of such 
interactions can expand our understanding of human physiology and reveal novel therapeutic 
targets. The identification and characterization of these interactions can be approached from 
different perspectives.  Chemists often use bioactive small molecules, such as natural products 
or synthetic compounds, as probes to identify therapeutically relevant protein targets. 
Biochemists and biologists often begin with a specific protein and seek to identify the 
endogenous ligands that bind to it. These interests have led to the development of methodology 
that relies heavily on synthetic and analytical chemistry to identify interactions, an approach that 
is complemented by in vivo strategies for validating the biological consequences of specific 
interactions.  
Untargeted metabolomics is a powerful strategy for the identification of novel protein-
small molecule interactions from various tissues that are relevant to target protein function 
during normal activity or within the context of a disease state.  Here, this platform was used to 
identify the first endogenous ligands, prostaglandins A2, B2, D2 and E2, for the orphan nuclear 
receptor Nurr1, a gene that is also linked to Parkinson’s Disease. These ligands function as 
inverse agonists of Nurr1 transcriptional activity and PGD2 and PGE2 have also been 
implicated in the neuroinflammatory pathway that contributes to PD progression.   
Further demonstrating the value of these approaches in answering important chemical 
and biological questions, the work presented here on targeting the insulin degrading enzyme 
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(IDE) in the context of diabetes, illustrates the effectiveness of using small molecule tools to 
identifying novel endogenous substrates that play important roles in glucose homeostasis. Here 
the first potent and physiologically active IDE inhibitor was to discover that IDE regulates the 
abundance and signaling of glucagon and amylin, in addition to that of insulin.  Importantly, 
under physiologic conditions that augment insulin and amylin levels acute IDE inhibition can 
lead to substantially improved glucose tolerance and slower gastric emptying.  These findings 
transform our understanding of IDE’s roles in glucose regulation, and demonstrate a potential 
therapeutic strategy of modulating IDE activity to treat type-2 diabetes. 
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Chapter 1 
 
Methods for the Elucidation of Protein-Small Molecule Interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from: 
McFedries, A, Schwaid, A, Saghatelian, A. Methods for the Elucidation of Protein-Small 
Molecule Interactions. Chem Biol. 20, 667-73 (2013)
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1.1 Introduction 
 A number of different types of molecular interactions enable life. These include the 
interactions between proteins, proteins and nucleic acids, and proteins and small molecules. 
Elucidating these interactions and understanding how they control biology is a major scientific 
goal. A number of approaches have been developed in recent years to identify protein-protein 
interactions [1-6] and protein-nucleic acid interactions [7-9]. Ribosome profiling, for example, 
elucidates interactions between the ribosome and RNA in cells to reveal novel sites of protein 
translation. While many methods exist for the characterization of biopolymer interactions, far 
fewer approaches exist to elucidate interactions between proteins and small molecules. In 
recent years, however, more of these methods are beginning to emerge.  
            The importance of protein-small molecule interactions (PSMIs) in drug discovery and 
protein-metabolite interactions (PMIs) in biology has driven the development of new methods 
that rely heavily on the integration of both synthetic chemistry and analytical chemistry. Here, 
we divide these methods into two categories: small molecule-to-protein and protein-to-small 
molecule strategies. This division separates problems that aim to identify the protein targets of a 
bioactive small molecule from problems focused on identifying the small molecule-binding 
partner of a suspected metabolite-binding protein.  
 
1.2 Small-molecule affinity methods  
One of the successes in using small molecules as affinity reagents is the identification of 
FKBP by the natural product FK506 [10]. This seminal work led to the discovery of new proteins 
and pathways that explained the mechanism of action of a potent class of immunosuppressant 
drugs [11]. In doing so, this work informed us about vital, but previously unknown, cellular 
pathways involved in the regulation of the cellular immune response. More generally, these 
studies highlighted the tremendous value of using bioactive small molecules to study biology. 
Other important examples, including the discovery of the histone deacetylase family with 
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trapoxin [12], reinforced the impact of chemistry in important biological discoveries, leading to 
the development of the field of chemical biology [13]. All of this is predicated on being able to 
use complex bioactive small molecules as affinity reagents, which often requires complex 
chemical syntheses and emphasizes the importance of organic chemistry in this problem.  
The increased use of small molecule screening approaches in biology has led to the 
identification of many bioactive molecules, leading to an increased demand for methods that 
can elucidate PSMIs. Affinity-based methods are still the most common approach used and 
leading methods have learned to integrate these approaches with modern proteomics to 
accelerate targeted discovery. Ong and colleagues, for example, have combined small 
molecule-affinity chromatography with stable isotope labeling of amino acids in cell culture 
(SILAC) [14], a quantitative mass spectrometry (MS)-based proteomics strategy (using an ion 
trap MS), to identify PSMIs on a proteome-wide scale [14, 15] (Figure 1.1). To demonstrate the 
generality of this approach seven different compounds, including kinase inhibitors and 
immunophilin ligands, were studied in this first example. Derivatives of each of these 
compounds were prepared and linked to solid support by a carbamate linkage, affording small 
molecule derivatized beads.  
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Figure 1.1 Affinity capture coupled to SILAC for small molecule target identification. Cells 
are grown in ‘heavy’ or ‘light’ media and subsequently lysed. These ‘heavy’ and ‘light’ cell 
lysates are separately incubated with beads that are modified with a small molecule of interest.  
Excess small molecule is added to the ‘light’ cell lysate and this soluble small molecule prevents 
any specific small molecule-protein interactions with the beads. After removal of the lysate 
bound proteins are eluted from the beads and the lysates are then combined for subsequent 
analysis using quantitative proteomics. The samples can be distinguished by mass 
spectrometry since proteins from each sample have different molecular weights, and therefore 
specific PMSIs can be identified by the higher concentrations of these ‘heavy’ proteins versus 
‘light’ proteins.     
 
In SILAC, cells are then grown in regular media (light) or specialized media (heavy) that 
replaces certain amino acids with stable isotope labeled derivatives (e.g. 13C6-arginine and 
13C6,15N2-lysine). The result is that the proteins in the ‘heavy’ cells have proteins that weigh 
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more than the exact same proteins in ‘light’ cells, and these proteins can be distinguished and 
quantified by mass spectrometry. SILAC is used to identify PSMIs by passing ‘light’ lysate over 
beads coated with the bioactive small molecule. Any proteins with affinity for the small molecule 
are retained. As a control, a soluble variant of the small molecule is added to the ‘heavy’ lysate 
before it is incubated with the small molecule-modified beads. This soluble compound has the 
effect of binding the target proteins and preventing their binding to the small molecules on the 
surface of the bead. The post-bead lysate samples are then combined and analyzed by mass 
spectrometry. The ratio of light-to-heavy can identify those proteins that are specifically enriched 
by the small molecule on the bead, and therefore identify any target proteins of the small 
molecule.  
The results from these initial experiments were excellent. All the compounds used 
identified known PSMIs, and several revealed some novel interactions. Moreover, by using 
compounds with different affinities for their targets, this work demonstrated that this method can 
successfully identify PSMIs with affinities from the low nanomolar (26 nM) to micromolar (44 
μM) range. This strategy has been applied to the identification of the primary targets of 
piperlongumine [16], a compound that was shown to selectively kill cancer cells in vitro and in 
vivo by targeting the stress response to reactive oxygen species (ROS) [17]. Overall, these 
types of affinity approaches have come to dominate the methods that are used to identify 
PMSIs. Examples include the identification of the nucleophosmin as a target of natural product 
avrainvillamide [18], the finding that cephalostatin A binds to specifically to members of the 
oxysterol binding-proteins, in the process revealing these proteins to be important in cancer cell 
proliferation[19].  
Importantly, affinity methods are not limited to synthetic compounds or natural products, 
but can also be used with endogenous metabolites. Specifically, Nachtergaele and colleagues 
demonstrated a direct binding interaction between 20(S)-hydroxycholesterol and the 
oncoprotein smoothened (Smo), a key protein in the sonic hedgehog (Shh) pathway, using a 
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derivative of 20(S)-hydroxycholesterol (nat-20(S)-yne) that was immobilized onto a solid support 
using Sharpless’ click chemistry [20]. This example highlights the generality of affinity-based 
approaches in identifying PSMIs. The only limitation appears to be the ability to access 
derivatives for immobilization by chemical synthesis and compounds that have or retain high 
affinity for their protein target. As scientists continue to gain interest in understanding the 
mechanism underlying bioactive small molecules, affinity-based methods will continue to be 
applied to many more target molecules.  
 
1.3 Proteomic target identification  
In cases where small molecules are difficult to modify, or the synthetic skill necessary to 
make such modifications are difficult to access, a new group of powerful proteomics methods to 
discover novel PSMIs can be used. These strategies rely on detecting differences in the stability 
between unbound and small-molecule bound proteins to identify the target(s) of a small 
molecule. Drug affinity responsive target stability (DARTS) is one such method [21].  
DARTS relies on the fact that proteins are more stable when bound to a metabolite, 
which makes them less susceptible to proteolysis. Lysates are compared in the presence and 
absence of a small molecule.  Proteins that bind to the small molecule are protected from 
proteolysis relative to the control sample, as indicated by mass spectrometry (Figure 1.2). Proof-
of-concept experiments revealed that mammalian target of rapamycin (mTOR), for example, is 
less susceptible to proteolysis in the presence of E4, an mTOR kinase inhibitor. Moreover, 
DARTS is generally applicable and was used with other enzyme-inhibitor pairs, such as the 
COX2-celecoxib pair.  
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Figure 1.2 Drug Affinity Responsive Target Stability (DARTS). Aliquots of a protein lysate 
are mixed with either a small molecule (+ ligand) or solvent control (-ligand) to identify PSMIs. 
These samples are then subjected to limited proteolysis and compared by gel electrophoresis 
and quantitative mass spectrometry. Protein targets are identified as those proteins that display 
increased protease resistance in the presence of the small molecule.  
 
Next, DARTS was used to characterize PSMIs for resveratrol, an anti-aging compound 
thought to act primarily through interactions with the sirtuin protein Sir1. Using a yeast and 
human lysates the authors discovered that eukaryotic initiation factor A (eIF4A) is a target of 
resveratrol, which demonstrates that DARTS is able to discover novel PSMIs. Importantly, the 
authors confirmed that at least some of the biology controlled by resveratrol is eIF4A dependent 
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because worms lacking eIF4A no longer show any anti-aging in the presence of resveratrol. 
Together these experiments demonstrate the value and utility of DARTS for discovering PSMIs.  
Most recently, a proteomics method called Stability of Proteins from Rates of Oxidation 
(SPROX) was developed to identify PSMIs in complex cell lysates [22-25]. Rather than relying 
on non-specific proteolysis, which can make downstream mass spectrometry experiments 
difficult to interpret, SPROX relies on the irreversible oxidation of methionine residues by 
hydrogen peroxide to report on the thermodynamic stability of a protein’s structure during 
chemical denaturation (Figure 1.3). Proof-of-concept SPROX experiments performed using 
yeast lysates validated this approach by identifying  known binders of the immunosuppressant 
drug cyclosporine A (CsA)  [23].  SPROX has also been used with resveratrol, identifying the 
known target, cytosolic aldehyde dehydrogenase, along with several novel interactions [25].  
SPROX requires that target proteins contain methionine residues, and multidimensional protein 
identification technology (MudPIT) [26, 27] analysis of SPROX experiments using yeast lysates 
demonstrated that 33% of the detectable proteins contain a methionine. 
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Figure 1.3 Stability of Proteins From Rates of Oxidation (SPROX). SPROX identifies the 
targets of a small molecule from a complex protein mixture by measuring the ligand-induced 
changes in the rate of methionine amino acid side chain oxidation by hydrogen peroxide. 
Aliquots of the cell lysate are incubated with either a small molecule or a solvent control and 
then incubated with increasing concentrations of guanidine hydrochloride. 
Ligand induced difference in target protein unfolding will impact the rate of selective methionine 
oxidation by hydrogen peroxide. Quantitative proteomic is used to compare levels of reduced 
versus oxidized methionine-containing peptides in each sample set (small molecule versus 
control) to determine the rate of target protein oxidation as a function 
of guanidine hydrochloride concentration. A shift of the transition midpoint for a protein between 
+ligand and –ligand samples indicates that the protein is a target for the small molecule in 
lysate.   
 
A SPROX-like method that uses s-methyl thioacetimidate (SMTA) labeling to detect 
amidination differences of proteins and protein-ligand complexes during chemical denaturation 
has also been explored [28]. This method requires target proteins to contain lysine residues or 
have a buried N-terminus in the native state. This method is particularly useful when a ligand of 
interest is not stable in hydrogen peroxide and therefore cannot be investigated by SPROX. 
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SMTA labeling and SPROX complement each other, covering a wider range of the proteome 
[28]. Studying the thermodynamic stability of proteins under denaturing conditions in the 
presence and absence of ligand is an effective target protein identification strategy. However, 
the two described approaches require relatively large concentrations of ligand, in the uM to mM 
range, although they provide the flexibility to use a variety of downstream quantitative proteomic 
techniques.   
1.4 Chemoproteomic target identification 
 Unfortunately, not all proteins are as active in lysates as they are within the context of a 
cell, and therefore some relevant PSMIs or PMIs may be missed when using lysates. Screening 
a spiroepoxide library for antiproliferative compounds, for example, revealed that the most 
relevant biological target of the active spiroepoxide is only targeted in a living cell, but was 
inactive once the cell was lysed [29]. Many molecular mechanisms can account for the 
difference between intact cells and lysates but the ultimate point is that it is difficult to exactly 
replicate cellular conditions in any type biochemical experiment. Since it is impossible to predict 
what PSMIs are sensitive to cellular conditions new chemoproteomic approaches have been 
developed to enable target identification within live cells.  
These methods rely on the use of small molecules that can covalently label their protein 
targets so that intracellular labeling events can be detected after cell lysis. Manabe and 
colleagues demonstrated the value of this approach with a modified natural product derivative in 
an effort to identify its protein target [30]. Potassium isolespedezate, a metabolite known to 
induce nyctinastic leaf opening in the motor cells of plants belonging to the Cassia genus, was 
derivatized with an iodoacetamide for covalent crosslinking to its target and an azide to enable 
enrichment and identification of the isolespedezate target by conjugation to a flag peptide using 
click chemistry. This approach led to the identification of 5-methyltetrahydropteroyltriglutamate-
homocysteine S-methyltransferase (MetE) as the isolespedezate target protein. This method, 
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while powerful, is mostly limited by the ability to synthesize natural product derivatives that can 
covalently label their target while maintaining the potency of the compound.  
 Most recently, a chemoproteomic strategy approach was developed for the identification 
of PMIs for the endogenous metabolite cholesterol. Cholesterol is a central metabolite with roles 
in membrane structure, metabolism, signaling and disease. While many important functions of 
this molecule are known, the full spectrum of proteins that interact with cholesterol is far from 
complete. Hulce and coworkers synthesized a series of cholesterol derivatives and controls 
containing a photocrosslinking diazirine group [31] (Figure 1.4). In practice, cells are irradiated 
by light after exposure to these sterol probes resulting in the covalent modification of any protein 
they bind. Addition of exogenous cholesterol blocks the overall labeling of these probes to 
validate that binding of these probes is occurring at cholesterol-specific binding sites.  
Subsequent to probe labeling, the probe is conjugated to biotin by copper-catalyzed 
cycloaddition of azides and alkynes (CuACC) [32] chemistry allowing for affinity enrichment of 
labeled proteins.  
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Figure 1.4 Identifying protein targets in cell culture. Cells grown in ‘heavy’ and ‘light’ media 
are treated with a cholesterol probe compound that has been modified to contain a diazirine 
moiety. In addition, excess cholesterol is also added to the ‘light’ sample and this will act to 
compete any specific cholesterol probe–protein interactions. The cholesterol probe is 
photocrosslinked to any bound protein targets in cells, and the cells are subsequently lysed. Any 
cholesterol probe–protein conjugates in this lysate are then modified with biotin using ‘click’ 
chemistry and labeled proteins are separated from cell lysate by affinity chromatography. The 
‘heavy’ and ‘light’ fractions are then mixed and examined by quantitative proteomics. Proteins 
that specifically bind cholesterol will have a higher ratio of ‘heavy’ to ‘light’ in the mass spectrum.  
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Integrating these sterol probes with SILAC [14] enables the identification of sterol probe-
target proteins. In these experiments, the probe is added to both ‘heavy’ and ‘light’ cells, but the 
‘light’ cells also contain a competitor (cholesterol) to block binding. Subsequent analysis of the 
‘heavy’ and ‘light’ samples identifies cholesterol-binding proteins as those proteins enriched in 
the heavy sample versus the control sample. The identification of several known cholesterol-
binding proteins such as Scap, caveolin and HMG-CoA reductase validated the methodology. 
Subsequent analysis of the entire data set using various bioinformatics tools revealed that 
almost every major class of protein has members that bind cholesterol, including GPCRs, ion 
channels and enzymes. More broadly, the analysis also revealed an enrichment of proteins 
involved in neurological disorders, cardiovascular and metabolic disease, demonstrating the 
potential therapeutic insights that may eventually be provided by this data.   
Together these examples demonstrate the utility of chemoproteomic approaches to 
identify PSMIs and PMIs, and highlight the power of these approaches to rapidly increase our 
understanding about the role of specific small molecules in biology.    
 
1.5 Biophysical identification of small molecule binders  
 In many cases, the problem of identifying a PMI begins with interest in a particular 
protein. This protein may be a potential drug target or it may be suspected to require small 
molecule binding to regulate its activity. There are numerous cell-based assays for GPCRs [33-
35] and nuclear receptors [36], for example. In general, these methods are highly effective. 
Such assays have already been reviewed extensively in the literature [33-36]. Instead, we’ve 
decided to focus on cell-free approaches that rely heavily on biochemical, biophysical and 
profiling methods to reveal PMIs for endogenous metabolites.  
Biophysical screening methods provide an effective means for PMI discovery from 
endogenous metabolites. Differential scanning techniques were originally developed to optimize 
recombinant protein stability (i.e. melting temperature (Tm)) for purification and crystallography 
14 
 
[37]. Differential static light scattering (DSLS) and/or differential scanning fluorimetry (DSF) are 
the two most commonly used methods. DSLS measured denaturation by tracking temperature 
induced increases in the intensity of scattered light, while DSF measured increases in the 
fluorescence from the environmentally sensitive dye SYPRO Orange. Shifts in melting 
temperatures of > 2 °C were found to confidently represent binding events and conditions that 
enhanced protein stability, and thermal shifts > 4 °C increased the likelihood of positive results 
in crystallographic screens. 
These methods have recently been extended to identify PMIs by measuring the effect of 
small molecules on the melting temperature (Tm) of proteins. The binding between a small 
molecule and protein stabilizes the protein structure (i.e. raises the Tm) (Figure 1.5).  Recently, 
DeSantis and coworkers used DSF to identify natural estrogen receptor alpha (ERα) ligands 
from a library of molecules (not from a complex mixture) [38] . DSF successfully identified 
known natural ERα agonists, β-estradiol and estrone, demonstrating the utility of this assay in 
characterizing natural PMIs. The authors suggest that these assays will be useful in the 
identification of unknown nuclear receptor ligands in the future.   
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Figure 1.5 Thermostability Shift Assay. PSMI and PMIs can be identified in a high-
throughput fashion by monitoring shifts in the melting temperature (Tm) of a protein-ligand 
complex versus a protein-solvent control. The environmentally sensitive dye SYPRO Orange 
emits when bound to hydrophobic amino acid residues and is used to monitor protein unfolding 
via differential scanning fluorimetry (DSF). 
 
1.6 Affinity-based identification of small molecule binders  
         Alternatively, affinity based experiments using immobilized proteins are another option 
for the characterization of PMIs.  In general, these assays provide the advantage that they can 
be performed with unmodified metabolite resulting in a reduced likelihood of false negatives.  
This approach relies on the fact that proteins can be immobilized without altering the secondary 
structure of the protein or interfering with ligand binding. The first examples of affinity methods 
relied on using radioisotopes to identify PMIs by measuring radioactivity of a protein after 
incubation and washing with a radiolabeled ligand [39, 40].  
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Most recently, this approach has been optimized in the form of a DRaCALA assay 
(Differential radial capillary action of ligand assay), which allows for the rapid high throughput 
identification of PMIs using radiolabeled metabolites [41]. DRaCALA utilizes the affinity of 
proteins for nitrocellulose membranes to sequester radiolabeled metabolites bound to protein.  
A solution containing the protein of interest and radiolabeled ligand is spotted on nitrocellulose.  
Unbound ligand will diffuse with the solvent throughout the membrane, whereas protein and 
ligand bound to protein will be immobilized at the point it was spotted. One advantage of 
DRaCALA is that it can avoid time-consuming protein purification by using whole cell lysate to 
identify PMIs as long as control cell lysate that does not express the metabolite-binding protein 
is available.  
The one disadvantage of this method is that it requires foreknowledge as to what 
candidate metabolites should be tested, and in that each metabolite must be tested individually. 
Nevertheless, for certain cases DRaCALA provides a high-throughput means to identify ligand-
binding proteins. The identification of prokaryotes that have proteins capable of binding bis-(3’-
5’)-cyclic dimeric guanosine monophosphate (cdiGMP), a metabolite important in biofilm 
formation, was accomplished by simply using lysates from 191 strains of P. aeruginosa and 82 
other bacterial strains. The ‘hits’ in this assay corresponded to those bacteria that have 
diguanylate cyclase (DGC), as expected. This approach precludes the identification of 
unexpected PMIs or PMIs with novel metabolites.  Still, DRaCALA remains a powerful approach 
for uncovering protein metabolite interactions.  
 The use of global mass spectrometry approaches allows for the scrutiny of a larger pool 
of metabolites, including novel metabolites, and can result in the unbiased identification of 
protein metabolite binding. Specifically, the use of global metabolite profiling enabled the 
development of a novel, unbiased, strategy for the identification of endogenous PMIs [42] 
(Figure 1.6). In this approach, recombinant proteins fused to an affinity tag—either GST or 
hexahistidine—are immobilized on a solid support. Incubation of these proteins with a 
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metabolite mixture, typically an extract containing the entire lipidome from a cell or tissue of 
interest results in the formation of a protein-metabolite complex on the bead. Following this 
incubation, the protein is washed, subsequently eluted from the solid support, and the eluent is 
then analyzed using a liquid chromatography–mass spectrometry (LC–MS) metabolite profiling 
platform (using an ESI-TOF for the MS). Quantitative comparison of the metabolite profiles 
between samples with and without protein reveals any metabolites that are enriched by the 
protein. 
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Figure 1.6. Affinity methods for elucidating PMIs. A) Protein (blue) is immobilized on a solid 
support (grey) and incubated with lipids from tissue lysate. The immobilized protein is then 
washed and the protein is eluted from the beads. The eluate is then analyzed by LC–MS and 
compared to eluate from a control sample (solid support with no protein) by in order to identify 
specific PMIs. B) A yeast strain bearing either the protein of interest fused to an IgG epitope tag, 
or the IgG epitope tag only, was lysed and immunoprecipitated using antibody labeled beads.  
Lipids were then extracted from the beads and examined by LC–MS.  Comparison between the 
protein and control sample can be used to identify any specific PMIs. 
 
         This approach was developed using three different lipid-binding proteins with known 
ligands: cytosolic retinoic acid binding protein 2 (CRABP2), fatty acid binding protein 2 (FABP2) 
and StarD3. The strategy successfully identified specific PMIs for all three of these proteins, and 
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in doing so created a reliable method to pulldown protein metabolite interactions [42].  It does 
not require any explicit knowledge about the identity of the metabolite and can be conducted 
rapidly against a large pool of metabolites.  Moreover, it was not susceptible to the enrichment 
of nonspecific metabolites.  Although the examples presented here centered on lipids, there is 
no reason this approach could not be used for polar metabolites as well. This strategy has been 
successfully applied to other PMIs, including the discovery that arachidonic acid and 
docosahexanoic acid, polyunsaturated fatty acids, bind to the orphan nuclear receptor Nur77 
[43].   
Li and colleagues developed an exciting strategy to identify PMIs within yeast [44] 
(Figure 1.6). Specifically, they focused on interaction with yeast protein kinases as well as 
proteins that comprise ergosterol pathway. The proteins in this group were epitope tagged to 
enable their immunoprecipitation of from cellular lysates. These immunoprecipitated samples 
were analyzed by metabolomics to identify any endogenous metabolites bound to the proteins. 
As a control, each sample was also checked by SDS-PAGE to ensure pulldown of the target 
protein was successful.  
Comparison of the metabolite profiles from these various samples revealed a number of 
new interactions. Many of the enzymes within the ergosterol pathway bound to sterol 
intermediates, which suggest that these molecules exert regulation on the pathway. 
Interestingly, it was also discovered that some of the proteins within the ergosterol pathway bind 
to pentaporphoryin, which was a complete surprise but helps explain a previous observation 
linking pentaporphoryin and ergosterol regulation. Furthermore, their analysis led to the 
discovery that a number of yeast protein kinases are regulated by ergosterol to highlight the 
generality of this method towards numerous protein classes. In aggregate, this data highlights 
the potential for unbiased PMI identification to greatly increase our current understanding of 
endogenous small molecule biology.  
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1.7 Future Directions 
A successful library of approaches to determine PSMIs and PMIs has been developed, 
and is ready to be applied to identify unknown PMIs of interest. These approaches enable the 
discovery of novel interactions and are also designed to maximize the likelihood that the 
interactions are occurring in cells and tissues. The continued application of these methods will 
enrich our understanding of small molecule biology and also stimulate the development of 
improved methods for discovering these interactions. As demonstrated by the above examples 
this research area sits squarely at the interface of chemistry and biology and will greatly benefit 
from collaboration between future generations of chemists, biochemists and biologists.  
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Chapter 2 
Metabolomics Strategy Discovers Endogenous Inverse Agonists of the 
Orphan Nuclear Receptor Nurr1   
27 
 
 
2.1 Introduction 
 Nuclear receptors are a family of ligand-dependent transcription factors that respond to 
the environment of a cell by binding to a diverse battery of signaling molecules, such as 
oxysterols (LXR), vitamin D (VDR), estrogen (ER) and cortisol (GR)1-3. These receptors directly 
affect the expression of their target genes and play a central role in regulating genetic programs 
that control physiology related with numerous processes, including development and 
metabolism 2. In addition to a role in normal physiology, nuclear receptor dysfunction is 
associated with diseases such as diabetes and cancer 1, 4. As powerful regulators of physiology 
nuclear receptors are also targets of approved drugs, such as Advair (targeting GR for asthma 
and COPD) and Avandia (i.e. Rosiglitazone; targeting PPARγ for type II diabetes)5 . 
Nuclear receptors have a well conserved domain architecture composed of a highly 
variable N-terminal ligand-independent activation function (AF-1), a central DNA binding domain 
(DBD), a flexible hinge region and a C-terminal ligand-binding domain (LBD) that contains a 
ligand-dependent activation function (AF-2) 1, 6.The DBD contains two well conserved zinc 
fingers motifs that mediate receptor binding to specific DNA sequences, called hormone 
response elements (HRE), in the promoter region of target genes. The LBD is responsible for 
the recognition of the small molecule ligand, receptor dimerization, and the recruitment of co-
regulator proteins to initiate transcription 2. Members of the nuclear receptor superfamily share 
structural homology in their ligand binding domain (LBD), which is composed of 12 α-helices 
and 2-3 -strands that are arranged as a three layered, antiparallel sandwich 1, 2.  
At the molecular level the canonical nuclear receptor uses a conformational change 
upon binding of a small molecule ligand to control gene transcription. The mechanism of nuclear 
receptor activation can be described as a switch between associations with co-repressor and 
co-activator proteins driven by ligand-dependent positioning of the C-terminal alpha helix of the 
LDB (helix 12) 6. In the absence of ligand, helix 12 occupies the co-activator binding surface and 
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facilitates co-repressor association with the receptor. Binding of an agonist induces a critical 
conformational change in the positioning of helix 12 that leads to the exchange of co-repressor 
(SMRT/NCOR and HDAC complexes) for co-activator proteins (HAT and chromatin remodeling 
complexes) 6-9 at a hydrophobic interface composed of residues from H12, H3 and H4 1, 10. 
Recently, the Saghatelian lab developed a metabolomics approach for elucidating 
protein-metabolite interactions and applied this approach to identify candidate endogenous 
ligands for the orphan nuclear receptor Nur77 (NR4A1). The NR4A subfamily contains two other 
members, Nurr1 (NR4A2) and Nor1 (NR4A3), also considered to be orphans or known 
members of the nuclear receptor family that lack any currently accepted ligand 11, 12. We 
became interested in this class of nuclear receptors because they are widely expressed in 
energy demanding tissues (liver, brain, skeletal muscle and adipose), where they regulate 
essential pathways involved in metabolism and development such as gluconeogenesis (Nur77) 
11, 13, 14, the development of dopaminergic neurons (Nurr1)15, 16, and lipid, carbohydrate and 
energy metabolism (Nor1) 12.  
The NR4A subfamily is characterized by atypical LBDs that lack both a canonical ligand 
binding pocket and a classical co-regulator interface 10, 17. Previously, Nur77 and Nurr1 were 
reported to be constitutively active nuclear receptors that did not have or need a ligand to 
function. This conclusion was supported by the apo-LBD crystal structures of Nurr1 (PDB: 
1OVL) 10 and Nur77 (PDB: 1YJE, 2QW4) 17  that indicated that the ligand binding domain of the 
receptors are filled with large, hydrophobic residues and, therefore, do not require a ligand. 
These crystal structures also showed that polar residues that did not associate with co-
regulators populated the classical, hydrophobic, co-regulator interface. However, a novel co-
regulator-binding cleft has been identified, composed of residues from helices 11 and 12. Co-
repressor proteins are capable of interacting with this surface, but to date no co-activator 
proteins have been found to bind to the NR4A LBD 18, 19. From this data it appears that the 
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N4RA family is unique in that it does not require a ligand to operate and does not use the 
canonical NR co-activators to modulate activity.  
However, other data, at least in terms of ligand binding (Figure 1), suggest another story. 
First, prostaglandin A2 was identified as a NOR1 agonist through screening 20. This indicates 
that there exist endogenous lipids that are able to bind and regulate the activity of members of 
the NR4A family. In addition, two small-molecule agonists of Nur77 have been reported, 
cytosporone B 21 and 1,1-bis(3-indolyl)-1-(p-methoxyphenyl)methane (BIM) 22, which indicate 
that Nur77 transcriptional activity can be regulated by the binding of a small molecule.  
Regarding Nurr1, its activity can be activated by both benzimidadole (BEN) 23, 24 and 
isoxazolopyridinone (IXP) derivatives 24, but it is unclear if these compounds interact directly 
with the receptor. These finding prompted the search for a natural ligand for X using 
metabolomics. The application of this strategy revealed that Nur77 binds polyunsaturated fatty 
acids (PUFAs; arachidonic and docosahexanoic acids)25. Here, I apply this metabolomics 
approach to identify candidate ligands for the NR4A family member Nurr1 and characterize the 
impact of lipid binding on the receptor’s transcriptional activity to identify bona fide endogenous 
ligands. 
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Figure 2.1 Ligands for the NR4A receptors include the Nor1 agonist prostaglandin A2, the two 
Nur77 agonists BIM and Cytosporone B (boxed functional groups have properties reminiscent of 
endogenous lipids), and the Nurr1 activating derivatives of benzimidole and 
isoxazolopyridinone. Arachidonic acid has recently been identified inverse agonist of Nur77.  
 
2.2 Identify natural ligands for Nurr1 through an untargeted metabolomics approach 
To determine candidate ligands for the human Nurr1 receptor an untargeted 
metabolomics approach to identify protein-metabolite interactions (Figure 2) 26-28 will be used. 
Lipids for this experiments were prepared from mouse brain tissue because Nurr1 activity is 
essential for the development and maintenance of dopaminergic neurons in the brain.  
The general strategy to identify protein-metabolite interactions begins with the 
recombinant expression and purification of the Nurr1 LBD (residues 328-598) with an N-terminal 
His6 tag in Escherichia coli BL21(DE3) cells. To identify molecules that bind specifically to the 
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LBD it is immobilized on a metal ion affinity chromatography (IMAC) Sepharose 6 Fast Flow 
resin, where it is incubated with a pool of candidate lipids extracted from wildtype mouse brain. 
In this experiment, incubation of the resin in the absence of protein allows us to control for 
nonspecific binding of lipid to the solid support. After incubation the extract is filtered, the beads 
and protein are washed and the nuclear receptor is eluted from the resin. Eluted samples are 
then analyzed using an untargeted liquid-chromatography-mass spectrometry (LC-MS) based 
metabolomics platform that allows for the identification of lipids that are enriched in the protein 
containing sample versus the controls.  
This system requires that use of internal standards to assist in the calculation of fold 
changes between metabolites in the sample sets 26-28. Metabolite profiles, the LC-MS 
chromatograms from each sample, are compared using a software program called XCMS that 
aligns the corresponding peaks in each sample and calculates their intensities by integrating the 
area under the curves 29. The differences in ion intensities between sample peaks are ranked by 
statistical significance (Student’s t-test) and assigned a fold change value that is normalized to 
the internal standards 26-29. Finally, we will identify the structure of enriched ions by using 
accurate mass (obtained during our standard MS experiments) and searching metabolite 
databases, such as METLIN, PubChem, or the lipid MAPS databases, for metabolites with 
similar molecular formulas 28.  
  
32 
 
 
 
 
Figure 2.2 A liquid chromatography-mass spectrometry (LC-MS)-based metabolomics 
approach for characterizing endogenous nuclear receptor (NR) ligands. In the first step, 
metabolites isolated from cells and tissues are incubated with the ligand-binding domain (LBD) 
of an NR that has been immobilized onto a solid support (left). During the incubation any 
endogenous ligands can bind to the NR and form a protein-metabolite complex (middle). 
Unbound metabolites are then washed away and the nuclear receptor-ligand complex is eluted 
from the resin. NR-bound metabolites are identified by comparing the LC-MS chromatograms 
from the nuclear receptor sample to control sample using the program XCMS (right). 
 
From the metabolomics assay I found that the Nurr1 LBD enriched polyunsaturated fatty 
acids (PUFAs) (p-value < 0.05 and fold-change > 2) in comparison to the no-protein resin 
control sample (Table 1). To be confident that we have identified endogenous ligands of Nurr1, 
the candidates must bind with physiologically relevant dissociation constants (nM to uM range)30 
to the receptor and be capable of regulating LBD dependent transcription. The secondary 
biochemical assays that were perform to characterize the lipid-protein interaction were circular 
dichroism (CD), which was used to measure conformational changes induced by lipid binding 25  
(Figure 3) and an intrinsic tryptophan fluorescent assay, which was used to monitor saturation 
binding (Figure 5)31. Additionally, the intrinsic tryptophan fluorescent assay was used to screen 
prostaglandins (Figure 4) for their ability to bind the Nurr1 LBD as precedence for their ability to 
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regulate nuclear receptor function, particularly that of members of the NR4A family has already 
been established20.  
 
Enriched Lipids Fold Change 
Docosapentaenoic acid (DPA, C22:5) 10.1 
Docosahexaenoic acid (DHA, C22:6) 7.7 
Arachidonic Acid (AA, C20:4) 7.1 
Oleic acid (C18:1) 7.1 
Linoleic (C18:2) 5.3 
No Enrichment (Controls) Fold Change 
Palmitic acid (PA, C16:0) 1.2 
Stearic (C18:0) 1.2 
Myristic   (C14:0) 1.1 
 
Table 2.1 Negative mode ions that are enriched by Nurr1-LBD greater than four-fold above 
the resin control across three separate experiments.  Polyunsaturated fatty acids (PUFAs) are 
enriched, while saturated fatty acids are not. Positive mode analysis of samples did not reveal a 
consistently enriched set of ions all three data sets.   
 
Quenching of intrinsic tryptophan (Trp) fluorescence can be used to measure candidate 
ligand binding. Excitation of Trp a 280nm will produce an emission at 330 nm when the residue 
is buried (hydropobic environment) and an emission at 350 nm when the residue is solvent 
accessible (polar environment).  One caveat of this strategy is binding events with no impact on 
the local environmental of Trp residues will not be identified, allowing for the occurrence of false 
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positives. The Nurr1 LBD (2 uM) was incubated with candidate ligands (50 um) in a screen of 
saturated fatty acids, PUFAs and Prostaglandins (Figure 4).  The fluorescence spectra is 
quenched upon treatment with the unsaturated fatty acids Oleic (18:1), Arachidonic (20:4) and 
Docosahexaenoic (22:6) as well as with the Prostaglandin B2, while remaining relatively 
unchanged by the addition of saturated fatty acids and other prostaglandins. Furthermore, 
titration assays showed that the PUFAs and PGB2 were able to saturate binding (Figure 5). 
Indicating that the PUFAs and prostaglandins have the potential to be bona fide Nurr1 ligands. 
To confirm the ability of the candidate ligands to modulate Nurr1 function, a cell based 
luciferase reporter assay was used to measure the regulation of downstream transcriptional 
activity in the presence of each candidate ligand. PUFAs and PGs did not have a significant 
impact on transcriptional activation on their own. However, treatment of cells with a 
benzimidazole activator (AROZ)24 followed by treatment with the candidate ligands identified 
prostaglandins PGA2, PGB2, PGD2, and PGE2 as inverse agonists. PUFAs had no significant 
impact on Nurr1 LBD dependent transcriptional activity, but there could be a variety of reasons 
for this, such as their metabolism in these cell lines. The identification of PGs as inverse 
agonists of Nurr1 is a novel finding, and would suggested increased inflammation would reduce 
dopamine production, which is consistent with the implication of prostaglandin signaling in the 
development of Parkinson’s Disease32.  
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Figure 2.3 Circular Dichroism of Nurr1-LBD and candidate ligands 
Circular Dichrosim spectra of Nurr1-LBD (5uM) after incubation with candidate ligands (50 uM) 
demonstrates that a variety of lipids can shift the secondary structure of the protein. 
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Figure 2.4 Intrinsic tryptophan fluorescence screen for lipid binding by Nurr1-LBD 
The Nurr1-LBD was excited at 280 nM and its fluorescence monitored between 300-450 nM in 
the presence of 25 molar equivalents of candidate ligand. The fluorescence spectra is lowered 
upon treatment with the polyunsaturated fatty acids  Oleic (18:1), Arachidonic (20:4) and 
Docosahexaenoic (22:6) as well as with the Prostaglandin B2,  while remaining relatively 
unchanged by the addition of saturated fatty acids and other prostaglandins. 
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Figure 2.5 Saturation binding curves using intrinsic tryptophan fluorescence  
Ligand-binding curves for palmitic acid (PA), arachidonic acid (AA), oleic acid, prostaglandin B2 
(PGB2), prostaglandin A2 (PGA2) and prostaglandin E2 (PGE2) were constructed by plotting the 
change in fluorescence (relative to 0μM lipid) at the maximum emission wavelength (332 nM) 
versus ligand concentration. With increasing concentrations of AA and Oleic acid (Kd ~33 μM) 
and PGB2 (Kd ~105 μM) you see a saturating fluorescence response, while there is relatively 
no change for PA of PGA2.     
2.3 Conclusions 
 The PUFAs and PGs identified here are the first endogenous lipids identified to have a 
regulatory impact on Nurr1 function. This finding demonstrates the effectiveness and value of 
using an untargeted metabolomics approach to discover novel small molecule–protein 
interactions with bioactive properties. The fact that PGs, most specifically PGD2 and PGE2, 
have been implicated in the neuroinflammatory pathway contributing to the progression of 
Parkinson’s Disease, positions this work to inform future research in targeting that pathway for 
therapeutic development.  Additionally, future structural studies will be important for the 
identification and description of the NR4A unique mechanism of ligand-dependent 
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transactivation. This piece of work has deorphanized Nurr1 and will hopefully serve as a starting 
point for developing novel therapeutics that target the activity of this receptors for the treatment 
of Parkinson’s disease. 
2.4 Methods 
Recombinant Nurr1LBD Expression (His6-Nurr1LBD) and Purification. Nurr1 LBD 
(residues 328-598) with an N-terminal His6 tag was synthesized into the PJexpress411 vector 
by DNA2.0.  1-2L cultures of Escherichia coli BL21(DE3) cells that had been transformed with 
PJexpress411-His6-Nurr1LBD were grown with shaking in 2YT broth plus 50 µg/mL kanamycin 
until mid-log phase, then induced with 1mM IPTG for 4 hours. Cells were harvested by 
centrifugation (10 min at 10,000g) and stored at -80ºC until purification.  
 For purification of His6-Nurr1LBD protein, ≤2L cell pellets were resuspended in 35 mL 
lysis buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 20 mM imidazole, 1% TritonX-100) and 
were lysed by sonication at 4ºC. Lysate was cleared by centrifugation at 10,000g for 15 min at 
4ºC. Soluble fraction was then loaded onto pre-equilibrated with lysis buffer nickel column 
(IMAC Sepharose 6 Fast Flow Resin from GE Heathcare). Column was washed with 50 mL 
lysis buffer and 100 mL was buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 20 mM imidazole), 
before application of 30 mL elution buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 500 mM 
imidazole). Eluate was concentrated using 10 kDa MWCO filter (Amicon). The protein was 
further purified by Superdex 200 10/300 GL column (GE Healthcare) in  SEC buffer (20 mM 
Tris-HCl pH 7.9, 100 mM NaCl). 
 
Tissue Extraction. An 8 mL solution of 2:1:1 CHCl3: MeOH: H2O was prepared for the 
extraction of 1 frozen mouse brain (Pel-freez Biologicals) in a 15-mL dounce tissue grinder. 
Sample was homogenized once ice until homogeneity was reached. Extract was then 
transferred to glass vials for centrifugation at 2,500 g for 20 minutes to separate organic and 
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aqueous layers. Organic (bottom) layer was removed and concentrated under stream of 
nitrogen gas. Extract was suspended in 200 uL of DMSO for use in enrichment experiments. 
Stored at -80C.        
 
Ligand enrichment experiments with His6-Nurr77LBD. A 10-μL suspension of IMAC 
Sepharose 6 Fast Flow resin (GE Healthcare) was added to a 0.8 mL centrifuge column (Pierce 
Scientific #89868) and charged with Ni2+ ions. The resins were washed with water (500μL and 
then 2×100μL) and equilibrated equilibration with 3×200 μL of SEC buffer (20 mM Tris-HCl pH 
7.9, 100 mM NaCl). Subsequently, the charged resins were incubated with either (i) 200 μL of 
25μM His6-Nurr1LBD solution (experiment) or (ii) 200 μL protein SEC buffer (control). After 2 h 
incubation at 4 °C, the unbound protein was separated from the resins by centrifugation, and the 
resins were washed with 20 mM imidazole buffer (3× 200 μL). The lipid mixture (200 μL) was 
then prepared as a solution in protein buffer containing 4% (v/v) DMSO (i.e., the mixture of 8 μL 
lipid extracts in DMSO (or DMSO for no lipid control), and 192 μL protein buffer). After the resins 
were incubated with the lipid mixture for 1 h at room temperature, the lipid mixture was removed 
by centrifugation, and the resins were washed again for the last time with 20 mM imidazole 
buffer (3×200 μL). In the last step, the elution of the protein or any metabolite-bound protein was 
accomplished by incubating the resins with 100 μL of elution buffer (20 mM Tris-HCl pH 7.9, 100 
mM NaCl, 500 mM imidazole) for 5 min prior to centrifugation. This step was repeated three 
times. The elution fractions were combined, and the sample was stored at -80 °C until it was 
analyzed by LC-MS. 
 
LC-MS analysis of eluates from ligand enrichment experiment. LC-MS analysis was 
performed using an Agilent 6220 LC-ESI-TOF instrument. For the LC analysis in the negative 
mode, a Gemini (Phenomenex) C18 column (5 µm, 4.6 mm x 50 mm) and precolumn (C18, 3.5 
µm, 2mm x 20mm) were used. Mobile phase A was a 95/5 water/methanol solution and mobile 
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phase B was a 60/35/5 isopropanol/methanol/water solution. Both mobile phase A and B were 
supplemented with 0.1% ammonium hydroxide as a solvent modifier. The flow rate was set to 
0.5 mL/min throughout the duration of the gradient. The gradient began at 0% B for 12 minutes 
(first 10 minutes directed to waste) and then linearly increased to 100% B over the course of 40 
min, followed by an isocratic gradient of 100% B for 6 min before equilibration to 0% B for 7min.  
For LC analysis in the positive mode, a Luna (Phenomenex) C5 column (5 µm, 4.6 mm x 
50 mm) and precolumn (C4, 3.5 µm, 2mm x 20mm) was used. Mobile phases A and B and 
gradient remained the same as used in negative mode, except 0.1% formic acid and 5 mM 
ammonium formate were used as solvent modifiers. The capillary voltage was set to 4.0 kV and 
fragmentor voltage to 100V. The drying gas temperature was 350ºC and flow rate was 10L/min, 
with the nebulizer pressure at 45 psi. Data was collected in both centroid and profile modes 
using a mass range of 100-1500 Da. Each run was performed using 80 µL injections of eluates 
from the ligand enrichment experiments and 45 µL for lipid mixtures. 
 
LC-MS data analysis. Total ion chromatograms of eluates from the two sample sets 
(N=3) of His6-Nurr1LBD + lipids or no protein resin control +lipids was collected. Two step 
analyses was preformed, beginning with automated data analysis by XCMS followed by manual 
statistical analysis, confirmation and filtering of XCMS output files. To identify metabolites 
enriched by His6-Nurr1LBD the following parameters were used to filter XCMS output: fold 
changes ≥ 2, statistical signifigance (p < 0.05), and minimum MSII of 10,000 in samples of His6-
Nurr1LBD + lipids. Visual inspection of EICs and elimination of isotopic peaks followed. Finally, 
enriched lipids were confirmed to be present in applied lipid mixture.  
 
Circular Dichroism (CD) Spectroscopy. CD spectroscopy was performed on a Jasco 
J-710 spectropolarimeter.  A chilled 200 uL mixture prepared containing 5 uM His6-Nurr1LBD 
(20 mM Tris-HCl pH 7.9, 100 mM NaCl) and 50 µM of candidate ligand in ethanol (or equivalent 
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volume of pure ethanol for control), with the ethanol concentration not to exceed 5% (v/v). The 
sample was then transferred to a quartz glass cuvette with 1-mm path length and scanned in 
quadruplicate at 20ºC across the wavelengths of 260 nm to 190 nm. To obtain the final CD 
spectrum, the raw data was subtracted i.e. protein containing sample minus buffer control, 
smoothed using Savitzky-Golay method with the convolution width of 5 and calculated for molar 
ellipticity values.  
 
His6-Nurr1LBD intrinsic tryptophan fluorescence binding assay. In a 96 well 
standard, opaque plate 2 µM His6-Nurr1LBD protein was mixed with 50 µM candidate ligand 
(DMSO ≤5% v/v) in protein buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl). Data was collected 
on a SpectraMax M5 Microplate Reader using an excitation wavelength of 280 nm, with 
emission wavelength monitored between 300 to 450 nm, using a step size of 1 nm. Additional 
settings: PMT sensitivity set to high, no cutoff selected, autocalibrate turned on, automix turned 
off, and precision set to 14.  
 
Transient Transfection and Reporter Analysis. To quantify Nurr1 transcriptional 
activity, CV1 cells or HEK293 cells in 48-well plates were transfected with 100ng/well NBRE-
luciferase or NurRE-luciferase reporter, 50ng/well Nurr1, together with 50ng/well CMV--gal 
reporter (as internal control for transfection efficiency). NurRE-luc and Nurr1 plasmids were 
generously provided by Dr. Orla Conneely (Baylor College of Medicine). NBRE-luc plasmid was 
generously provided by Dr. David Mangelsdorf (UT Southwestern). All transfection was 
performed using FuGENE HD (Roche) (n=3) and repeated for at least three times. The cells 
were treated with each compound or vehicle control 24 hrs after transfection. Reporter assays 
were conducted 48 hrs after transfection, and luciferase activity was normalized by -gal 
activity.  
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Chapter 3 
Anti-Diabetic Activity of Insulin-Degrading Enzyme Inhibitors Mediated by 
Multiple Hormones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from: 
 
Maianti, JP, McFedries, A, et. al.. Anti-Diabetic Activity of Insulin-Degrading Enzyme Inhibitors 
Mediated by Multiple Hormones. Nature. Accepted 2014. 
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3.1 Introduction 
The dynamic interplay between the production and proteolytic degradation of peptide 
hormones is a key mechanism underlying the regulation of human metabolism.  Inhibition of the 
peptidases and proteases that degrade these hormones can elevate their effective 
concentrations and augment signaling.  In some cases, the resulting insights can lead to the 
development of novel therapeutics1.  Dipeptidyl peptidase 4 (DPP4) inhibitors, for example, are 
anti-diabetic drugs that increase the concentration of the insulin-stimulating hormone glucagon-
like peptide 1 (GLP-1), resulting in elevated insulin concentrations and lower blood glucose 
levels2.  Researchers have speculated for at least six decades that insulin signaling could also 
be augmented to improve glucose tolerance by inhibiting its degradation3,4.  The zinc 
metalloprotease insulin-degrading enzyme (IDE) is thought to be the primary enzyme 
responsible for inactivation of insulin in the liver, kidneys, and target tissues3,4.  Recently, 
genome-wide association studies have identified predisposing and protective variants of the IDE 
locus linked to type-2 diabetes (T2D)5-9, suggesting a functional connection between IDE and 
glucose regulation in humans. 
 Based on the known biochemistry of IDE, inhibition of this enzyme is expected to elevate 
insulin levels and augment the response to glucose3,4.  While mice lacking a functional IDE gene 
(IDE–/– mice) have elevated insulin levels, counterintuitively these animals exhibit impaired, 
rather than improved, glucose tolerance10,11.  Physiological studies with IDE–/– mice concluded 
that chronic elevation of insulin in these animals results in a compensatory lowering of insulin 
receptor expression levels, which leads to impaired glucose clearance following a glucose 
load10,11.  This model raises the possibility that in the absence of such compensatory effects, 
acute inhibition of IDE may lead to improved physiological glucose tolerance.   
 Acute inhibition of enzymes is typically achieved through the use of small-molecule 
inhibitors, but the only previously reported IDE inhibitors are analogs of the linear peptide 
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mimetic Ii1 (Fig. 3.1)12,13, which is highly unstable in vivo11.  These compounds derive potency 
from a zinc-chelating hydroxamic acid group, which has the potential to interact strongly with 
other metalloproteases and metal-binding proteins14.  These observations highlight the need for 
a selective small-molecule IDE inhibitor to characterize the biological functions and therapeutic 
relevance of this enzyme in vivo15,16, uncoupled from confounding physiological adaptations that 
arise in IDE knock-out mice10,11.  In this study we set out to discover potent and selective small-
molecule IDE inhibitors that are active in vivo, and to use these compounds to reveal the 
physiological consequences of IDE inhibition. 
3.2 Potent and selective IDE inhibitors 
 Ralph Kleiner and Juan Pablo Mainanti in the Liu lab led the discovery of small-molecule 
modulators of IDE, we performed in vitro selections on a previously described DNA-templated 
library of 13,824 synthetic macrocycles17,18 for the ability to bind immobilized mouse IDE (Fig. 
A3.1).  This library previously yielded highly selective Src kinase inhibitors,19,20 and its unbiased 
design features and structural diversity suggested it may also contain ligands for other classes 
of proteins.  Since each macrocycle in this library is attached to a unique DNA oligonucleotide 
that can be used to identify the structures of IDE-binding macrocycles18,19, we used high-
throughput DNA sequencing revealed the macrocycle-encoding DNA templates that were 
enriched following in vitro selection.  Two independent IDE selection experiments, resulted in 
the identification of six putative IDE-binding macrocycles that share common structural features 
(Fig. 3a, Fig. A3.1).   
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Figure 3.1 Discovery of potent and highly selective macrocyclic IDE inhibitors from the in 
vitro selection of a DNA-templated macrocycle library.  a, Structure of the most potent hit 
from the IDE selection (6b) and a summary of the requirements for IDE inhibition revealed by 
the synthesis and evaluation of 6b analogs.  b, IDE inhibition potency of selection hits 1b to 6b 
and 30 structurally related analogs in which the linker, scaffold, and three building blocks were 
systematically varied.  c, Structure of physiologically active IDE inhibitor 6bK.  d, Structure of 
the inactive diastereomer bisepi-6bK.  e, Structure of the previously reported substrate-mimetic 
hydroxamic acid inhibitor Ii112.  (F) Selectivity analysis of macrocycle 6bK reveals > 1,000-fold 
selectivity for IDE ( , IC50 = 50 nM) over all other metalloproteases tested.  g, Inhibitor Ii1
12 
inhibits IDE ( IDE, IC50 = 0.6 nM), and also thimet oligopeptidase ( THOP, IC50 = 6 nM) and 
neurolysin ( NLN, IC50 = 185 nM), but not neprilysin ( NEP), matrix metalloprotease 1 
( MMP1), or angiotensin converting-enzyme ( ACE).  Human IDE shares 95 % primary 
sequence homology with mouse IDE24, and both are inhibited by the macrocycles used in this 
study with similar potency (Fig. A2.2).    
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 We synthesized these six macrocycles without their oligonucleotide templates and without 
the 5-atom macrocycle-DNA linker using solid- and solution-phase synthesis as either of two 
possible cis- or trans-alkene stereoisomers18,19 (Fig. A3.1). Biochemical assays revealed that 
four of the six trans-macrocycles assayed were bona fide inhibitors of IDE with IC50 ≤ 1.5 µM 
(Fig. A3.1).  The most active inhibitor among the library members enriched in the selection, 20-
membered macrocycle 6b (Fig. 3.1a), potently inhibited human IDE (IC50 = 60 nM).  The ability 
of 6b to inhibit IDE proteolytic activity in vitro was confirmed by three complementary assays 
using a fluorogenic peptide, an insulin immunoassay, and a calcitonin-gene related peptide LC-
MS assay (Fig. A3.2)21. 
 We synthesized and biochemically assayed 30 analogs of 6b in which each building block 
was systematically varied to elucidate structure-activity relationships of these inhibitors (Fig. 
3.1b).  These studies revealed the structural requirements required for potent IDE inhibition by 
this new class of molecules, including a trans-fused 20-membered macrocycle, the 
stereochemistry of the macrocycle substituents, and the size, shape, and hydrophobicity of the 
A and B building blocks (Fig. 3.1a). In contrast to the strict requirements at positions A and B, 
different building blocks were tolerated at position C (Fig. 3.1b).  Based on these results, we 
identified the inhibitor 6bK (IC50 = 50 nM, Fig. 3.1c) as an ideal candidate for in vivo studies 
because it exhibits enhanced water solubility relative to 6b, and can be readily synthesized on 
gram scale16.   
 Because selectivity is a crucial feature of effective probes to elucidate physiological 
functions16, we next characterized the protease inhibition selectivity of 6bK.  This inhibitor 
exhibited ≥ 1,000-fold selectivity in vitro for IDE over all other metalloproteases tested: thimet 
oligopeptidase (THOP), neurolysin (NLN), neprilysin, matrix metalloprotease 1, and angiotensin 
converting-enzyme (Fig. 2.1f).  In contrast, the previously reported substrate mimetic 
hydroxamic acid inhibitor Ii112 (Fig. 2.1e) is not as selective and it potently inhibits IDE (IC50 = 
0.6 nM), THOP (IC50 = 6 nM), and NLN (IC50 = 185 nM) (Fig. 3.1g).  The remarkable selectivity 
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of 6bK, in contrast with the known promiscuity of some active site-directed metalloprotease 
inhibitors14, led us to speculate that the macrocycle engages a binding site distinct from the 
enzyme’s catalytic site.  This hypothesis was supported by double-inhibitor kinetic assays that 
revealed synergistic, rather than competitive, inhibition by macrocycle 6b and substrate mimetic 
Ii1 (Fig. A2.2). 
3.3 Structural basis of IDE inhibition 
 In collaboration with Markus Selegur’s lab, Juan Pablo and Zach Foda determined the 
molecular basis of IDE inhibition and selectivity by these macrocycles, we determined the X-ray 
crystal structure of catalytically inactive cysteine-free human IDE-E111Q22 bound to 6b at 2.7 Å 
resolution (Fig. 3.2, Fig. A3.3a).  The enzyme adopted a closed conformation and its structure is 
essentially identical to that of apo-IDE (PDB 3QZ2, RMSD = 0.257 Å).  Macrocycle 6b occupies 
a binding pocket at the interface of IDE domains 1 and 2 (Fig. 3.2a), and is positioned more 
than 11 Å away from the zinc ion in the catalytic site (Figs. 3.2b and 3.2c).  This distal binding 
site is a unique structural feature of IDE compared to related metalloproteases23, and does not 
overlap with the binding site of the substrate-mimetic inhibitor Ii112.  The structure suggests that 
by engaging this distal site, the macrocycle competes with substrate binding (Fig. A3.3) and 
abrogates key interactions that are necessary to unfold peptide substrates for cleavage24-26 (Fig. 
3.2d). 
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Figure 3.2 Structural basis of IDE inhibition by macrocycle 6b.  a, X-ray co-crystal structure 
of IDE bound to macrocyclic inhibitor 6b (2.7 Å resolution, pdb: 4LTE).  IDE domains 1, 2, 3, 
and 4 are colored green, blue, yellow, and red, respectively.  Macrocycle 6b is represented as a 
ball-and-stick model, and the catalytic zinc atom is represented as an orange sphere.  b, 
Electron density map (composite omit map contoured at 1σ) and model of IDE-bound 
macrocycle 6b interacting with a 10 Å-deep hydrophobic pocket.  c, Relative position of 
macrocycle 6b bound 11 Å from the catalytic zinc atom.  d, Overlay of the 6b model (surface 
rendering) on the IDE:insulin co-crystal structure (pdb: 2WBY)26.  e, Activity assays for wild-type 
or mutant human IDE variants in the presence of 6bK.  Mutagenesis of residues Ala479Leu () 
and Gly362Gln () hindered the inhibition potency of 6bK by > 600- and > 50-fold, respectively, 
compared to that of wild-type human IDE (). 
 
catalytic site 
6b 
6b 10 Å 
catalytic site exo site 6b insulin 
building-block A 
building-block B 
catalytic site 
Ala479 Ala198 Trp199
Gly362 Phe202 6b 
0%
20%
40%
60%
80%
100%
0.0001 0.001 0.01 0.1 1 10 100 1000
e
n
z
y
m
e
 i
n
h
ib
it
io
n
 
6bK concentration (µM) 
  hIDE WT
  G362Q IDE
  A479L IDE
a  
d  
c  
b  
e  
11 Å 
53 
 
 Because a section of the macrocycle was unresolved in the electronic density map, as 
observed with other ligands co-crystallized within the IDE cavity,12 we sought to test the 
relevance of our structural model of the macrocycle:IDE complex (Fig. A3.3) to macrocycle:IDE 
binding in solution.  We identified IDE mutations predicted by the structural model to impede 6b 
binding (Fig. 3.2e), prepared the corresponding mutant IDE proteins, and measured their 
abilities to be inhibited by 6b and 6bK.  In addition, we also synthesized 6b analogs designed to 
complement these mutations and rescue inhibitor potency (Fig. A3.4). Building block A (p-
benzoyl-phenylalanine in 6b) occupies a 10 Å-deep pocket in the crystal structure (Fig. 3.2b), 
defined by residues Leu201, Gly205, Tyr302, Thr316, and Ala479.  As predicted by the 
structural model, mutation of Ala479 to leucine decreased the potency of inhibitors 6b and 6bK 
more than 600-fold, consistent with a significant steric clash in the binding site between Leu479 
and the distal benzoyl group in building block A (Fig. 3.2e).  Replacement of the p-benzoyl-
phenylalanine building block with the smaller tert-butyl-phenylalanine, macrocycle 9, inhibited 
A479L-IDE with equal potency as wild-type IDE, consistent with the ability of the smaller 
macrocycle 9 to accommodate the added bulk of the leucine side chain (Fig. A3.4).  Likewise, 
building block B (cyclohexylalanine in 6b) makes contacts in the structure with the peptide 
backbone of residues Val360, Gly361, and Gly362 located on the lateral β-strand 13 of IDE 
domain 2.  These residues are thought to assist in unfolding of large peptide substrates by 
promoting cross-β-sheet interactions24-26. Mutation of Gly362 to glutamine decreased the 
inhibition potencies of 6b and 6bK at least 50-fold compared to wild-type IDE (Fig. 3.2e).  A 
modified macrocycle (13) in which the cyclohexylalanine building block was replaced with a 
smaller leucine residue inhibited G362Q IDE and wild-type IDE comparably, consistent with a 
model in which the smaller B building block complemented the larger size of the glutamine side 
chain (Fig. A3.4).   
 Together, these structural and biochemical studies provide strong evidence for the 
proposed distal binding site of 6b and demonstrate the ability of the DNA-templated macrocycle 
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library to provide inhibitors that achieve unusual selectivity by targeting residues beyond the 
catalytic site.  IDE is the only homolog of the M16 clade of metalloproteases, which is 
evolutionarily distinct from other zinc-dependent metalloprotease members and characterized 
by an inverted zinc-binding motif23-26.  This distinct phylogenetic origin, together with the unusual 
binding mode of these macrocyclic inhibitors to IDE, may contribute to the unusual specificity of 
6bK among proteases tested and encouraged us to explore the properties of 6bK in vivo. 
3.4 Inhibition of IDE in vivo 
 Next we characterized the stability, physicochemical, and pharmacokinetic properties of 
6bK.  This macrocycle displayed significant stability during incubations with plasma and liver 
microsome preparations (74 % and 78 % remaining after 1 h, respectively), suggesting that this 
compound may be sufficiently stable in vivo to inhibit IDE activity.  Plasma protein binding 
assays indicated that ~6 % of 6bK remains unbound and potentially available to engage its 
target at sites of insulin degradation, extracellularly or in early endosome compartments of 
target tissues3,12.  To measure plasma half-life in vivo, we treated mice by intraperitoneal (i.p.) 
injection of 80 mg/kg 6bK using a formulation of sterile saline and Captisol, a β-cyclodextrin-
based agent used to improve solubilization and delivery27.  Plasma and tissue concentrations of 
6bK were measured using isotope dilution mass spectrometry (IDMS) (Fig. A3.5).  Plasma 
levels of 6bK were detectable 5 min post-injection, reached peak concentration (> 100 µM) at 60 
min, and were maintained at a detectable level for at least 4 h (Fig. A3.5).  This circulation time 
is within the timescale for standard physiological experiments with live animals28,29.  We 
observed prompt biodistribution of 6bK into plasma, liver, kidney, and pancreatic tissues (Fig. 
A3.5).  We did not detect any 6bK in the brain, suggesting that this macrocycle may not inhibit 
IDE within brain tissues, where IDE activity is needed for the clearance of β-amyloid peptides10.  
Indeed, brain tissue levels of Aβ(40) and Aβ(42) peptides in mice injected with 6bK were 
unchanged 2 h-post injection compared to vehicle-treated controls (Fig. A3.6), consistent with 
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the inability of 6bK to inhibit IDE in the brain.  Collectively, these observations suggested the 
viability of 6bK as a potential in vivo IDE inhibitor probe in peripheral tissues of mice16. 
 To evaluate the ability of 6bK to inhibit IDE activity in vivo, we subjected non-fasted mice 
to insulin tolerance tests (ITT)29 following a single injection with 6bK (80 mg/kg) formulated in 
Captisol27.  The insulin injections were carried out 30 min post-injection, corresponding to the 
time of highest 6bK concentration in plasma (approximately 100 µM, ~1000-fold the IC50 for 
mouse IDE).  Following a subcutaneous insulin injection, mice treated with 6bK experienced 
lower hypoglycemia and higher insulin levels compared to vehicle controls (p < 0.01, Fig. A3.6 
and Fig. 3.4b).  In 1955, Mirsky used a similar ITT assay to suggest the feasibility of insulin 
stabilization by injecting rats with preparations of an undefined endogenous IDE inhibitor crudely 
fractionated from bovine livers (presumably a competitive substrate; see Appendix Table 1)30.  
 Our experiments with 6bK provide the first evidence that a well-defined, selective, and 
physiologically stable pharmacological IDE inhibitor can augment the abundance and activity of 
insulin in vivo.  Testing the macrocycle at several doses established an effective dose of 6bK of 
~2 mg/mouse i.p., representing 80 mg/kg for lean C57BL/6J mice (25 g), and 60 mg/kg for diet-
induced obese (DIO) mice (35-45 g).  These inhibitor doses were well tolerated, did not produce 
adverse reactions, or body weight loss (Fig. A3.6), and did not induce detectable behavioral 
abnormalities. 
3.5 Anti-diabetic activity of IDE inhibition during oral glucose administration 
 To determine the physiological consequences of acute IDE inhibition in vivo, we evaluated 
glucose tolerance of mice treated with 6bK.  We used two methods of glucose delivery, either 
oral gavage or i.p. injection,28 and two different mouse models, lean or DIO mice31,32.  These 
four conditions were chosen to survey the role of IDE activity under a broad range of 
endogenous insulin levels and insulin sensitivity28,31.  Oral glucose administration, for example, 
results in greater insulin secretion compared to injected glucose delivery (Fig. A3.7).  Passage 
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of glucose through the gut causes the release of GLP-1, which strongly augments glucose-
dependent insulin secretion2,31.  This phenomenon is referred to as the ‘incretin effect’ (Fig. 
A3.7) and is magnified in DIO mice31.  In addition, DIO mice display hyperinsulinemia and 
insulin resistance compared to lean mice, enabling us to test the consequences of IDE inhibition 
in a model that resembles early type-2 diabetes in humans32.  
 In all glucose tolerance experiments we included two control groups: vehicle alone, and 
the inactive isomer16 bisepi-6bK (Fig. 3.1c), which is identical to 6bK in chemical composition 
and bond connectivity, but has virtually no IDE inhibition activity (IC50 > 100 µM, Fig. 3.1c, see 
also Fig. A2.8).  As expected, administration of 6bK alone, without a glucose challenge, did not 
significantly alter basal blood glucose or hormone levels compared to control treatments (Fig. 
A3.8).  We then examined the effect of 6bK on blood glucose levels during an oral glucose 
tolerance test (OGTT).  Lean or DIO mice were fasted overnight for these experiments, and 
then treated with a single dose of 6bK, vehicle alone, or a matching dose of inactive bisepi-6bK.  
After 30 minutes, glucose was administered by oral gavage. 
 Importantly, both lean and DIO mice treated with 6bK displayed significantly improved oral 
glucose tolerance compared to vehicle or inactive bisepi-6bK control groups (Fig. 3.3 and Fig. 
A3.9).  Effects of similar magnitude on oral glucose tolerance in mice have been observed using 
several known human anti-diabetic therapeutics33-36.  The two control groups exhibited similar 
blood glucose profiles, indicating that the observed effects of 6bK on glucose tolerance are lost 
when the stereochemistry of 6bK is altered in a way that abolishes IDE inhibition. 
 To further test if the observed effects of 6bK are specific to its interaction with IDE, we 
repeated these experiments using IDE–/– knockout mice10,11.  Mice lacking IDE were unaffected 
by 6bK treatment, and exhibited blood glucose responses indistinguishable to that of the 
vehicle-treated cohort (Fig. A3.10).  These results indicate that the effects of 6bK are dependent 
on the presence of IDE.  
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 Collectively, these observations support a model in which IDE regulates glucose-induced 
insulin signaling, and therefore glucose tolerance, and demonstrate that acute IDE inhibition 
improves post-prandial glucose control in lean and DIO mice (Fig. 3.3a and 3.3b).  Together, 
these results represent the first time that IDE inhibition has been shown to improve blood 
glucose tolerance3,30. 
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Figure 3.3 Physiological consequences of acute IDE inhibition by 6bK on glucose 
tolerance in lean and DIO mice.  a and b, Oral glucose tolerance during acute IDE inhibition.  
a, Male C57BL/6J lean (25 g) mice were treated with a single i.p. injection of IDE inhibitor 6bK 
(, 80 mg/kg), inactive control bisepi-6bK (, 80 mg/kg), or vehicle alone () 30 min prior to 
glucose gavage (3.0 g/kg).  b, DIO mice (35-45 g) were treated with 6bK (, 60 mg/kg), and 
inactive control bisepi-6bK (, 60 mg/kg) or vehicle alone () 30 min prior to glucose gavage 
(3.0 g/kg).  c and d, Glucose tolerance phenotypes after i.p. injection of glucose (1.5 g/kg) in 
lean (c) and DIO (d) male mice treated with 6bK (), inactive bisepi-6bK (), or vehicle alone 
().  Area under the curve (AUC) calculations are shown in Extended Data Fig. 9.  All data 
points and error bars represent mean ± SEM.  Significance tests were performed using two-tail 
Student’s t-test, and significance levels shown are p < 0.05 (*) or p < 0.01 (**) versus the 
vehicle-only control group. 
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3.6 IDE inhibition during an injected glucose challenge leads to impaired glucose 
tolerance 
 Prior work using IDE–/– mice characterized the effect of i.p. glucose injections, therefore we 
repeated the above experiments with 6bK followed by i.p. injected glucose tolerance tests 
(IPGTTs) to provide a more direct comparison with the knockout animal experiments10,11.  In 
contrast to the observed improvement in oral glucose tolerance upon 6bK treatment (Figs. 3.3a 
and 3.3b), IDE inhibition with 6bK followed by a glucose injection (1.5 g/kg i.p.) resulted in 
impaired glucose tolerance after 2 h in both lean and obese mice compared to vehicle alone or 
bisepi-6bK-treated controls (Figs. 3.3c and 3.3d).  These changes in the glucose response 
profiles of lean mice treated with 6bK compared to vehicle controls resemble the reported 
differences between IDE–/– and IDE+/+ mice during similar IPGTTs10,11.  Moreover, DIO mice 
treated with 6bK followed by glucose injection displayed a biphasic response in which glucose 
levels are lower over the initial 30 minutes of the IPGTT, followed by a hyperglycemic “rebound” 
starting 1 h after glucose injection (Fig. 3.3d).  Both the suppression of peak glucose levels and 
the magnitude of the hyperglycemic rebound were dependent on 6bK dose, and neither effect 
was observed in cohorts treated with vehicle alone or inactive bisepi-6bK, indicating that the 
impaired glucose tolerance during an IPGTT correlates with IDE activity (Fig. 3.3, and Fig. 
A3.9).   
 Collectively, the results of the OGTTs and IPGTTs indicate that the route of glucose 
administration impacts the physiological response of 6bK-treated animals in ways that cannot 
be explained by a simple model in which IDE’s physiological role is only to degrade insulin.  
Instead, the IPGTT results strongly suggest a role for IDE in regulating other glucose-regulating 
peptide hormones in vivo.   
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3.7 IDE regulates multiple hormones in vivo 
 The biochemical properties of IDE and its substrate recognition mechanism23-25 enable this 
enzyme to cleave a wide range of peptide substrates in vitro (Appendix 3 Table 1).  Two 
glucose-regulating hormones, beyond insulin, that are potential candidates for physiological 
regulation by IDE during a glucose challenge are glucagon and amylin.  Purified IDE has been 
previously shown to cleave both peptides in vitro37-39, but neither hormone is known to be 
regulated by IDE activity in vivo.  Compared to insulin, glucagon is a modest in vitro IDE 
substrate (KM = 3.5 µM for glucagon versus KM < 30 nM for insulin)
37, although IDE is capable of 
degrading glucagon at a comparable rate if present in sufficiently high concentrations (kcat = 38 
min-1 for glucagon)38.  Amylin is also a substrate for IDE in vitro (KM = ~0.3 µM)
39.  Other 
proteases suggested to degrade glucagon include nardilysin, cathepsin B and D, in cells and in 
vitro40,41, and neprilysin, which was shown to play a role in renal clearance of glucagon42.  
However, none of these enzymes are known to regulate endogenous processing of hormones 
or modulate blood glucose levels.  To our knowledge, no proteases have been previously 
shown to degrade amylin in vivo39.   
 To begin to probe the possibility that glucagon or amylin is regulated in vivo by IDE, we 
measured the plasma levels of these hormones at 20 and 130 minutes post-glucose injection in 
DIO mice treated with 6bK or vehicle alone during an IPGTT (Fig. 3.4a).  Plasma collected 20 
minutes post-glucose injection showed elevated insulin and amylin levels, but unchanged 
glucagon levels, for the 6bK-treated cohort relative to the control group (Fig. 2.4a).  During the 
hyperglycemic rebound 130 min post-injection, glucagon levels for the 6bK group were strongly 
elevated above 200 pg/mL, compared with 90 pg/mL glucagon in control mice (Fig. 3.4a).  
Consistent with these elevated glucagon levels, expression of a gluconeogenesis transcriptional 
marker, G6Pase, was elevated in the livers of 6bK-treated mice compared to control mice (Fig. 
3.4a).  
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Figure 3.4 Acute IDE inhibition affects the abundance of multiple hormone substrates 
and their corresponding effects on blood glucose levels.  a, Plasma hormone 
measurements at 20 and 135 minutes post-IPGTT (Fig. 3.3d) for DIO mice treated with 6bK () 
or vehicle alone ().  RT-PCR analysis of DIO liver samples collected at 135 min post-IPGTT 
reveals 50 % higher glucose-6-phosphatease (G6Pase) and 30 % lower phosphoenolpyruvate 
carboxykinase (PEPCK) transcript levels for the 6bK-treated cohort () versus vehicle-only (V) 
controls ().  b to d, Blood glucose responses and abundance of injected hormones in lean 
mice 30 min after treatment with 6bK (, 80 mg/kg) or vehicle alone ().  b, Insulin s.c. (0.25 
U/kg) after 5-hour fast.  c, Amylin s.c. (250 µg/kg) after overnight fast.  d, Glucagon s.c. (100 
µg/kg) after overnight fast.  Trunk blood was collected at the last time points for plasma 
hormone measurements (insets).  All data points and error bars represent mean ± SEM.  
Significance tests were performed using two-tail Student’s t-test, and significance levels shown 
are p < 0.05 (*) or p < 0.01 (**) versus the vehicle-only control group. 
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 Because hormone abundance measurements can be difficult to interpret during 
fluctuations in blood glucose that in turn affect pancreatic hormone secretion, we performed 
additional studies to confirm the relationship between IDE activity and glucagon and amylin 
levels in vivo.  To more directly establish the effect of IDE inhibition on the clearance of insulin, 
amylin, and glucagon in vivo, we injected each of these three hormones into lean mice 30 min 
after treatment with 6bK or vehicle alone (Figs. 3.4b to 3.4d).  The 6bK-treated cohorts exhibited 
significantly stronger blood glucose responses to each of these hormones compared to vehicle 
controls; mice treated with 6bK experienced hypoglycemia during insulin tolerance tests (Fig. 
3.4b) and hyperglycemia following challenges with either amylin (Fig. 3.4c) or glucagon (Fig. 
3.4d) relative to control animals.  Similar to glucagon, acute amylin administration in rodents 
results in a transient increase in blood glucose levels through gluconeogenesis and activation of 
lactic acid flux from muscle tissue to the liver43.  Moreover, in each case the plasma level of the 
hormone injected remained elevated at the end of the procedure in 6bK-treated mice relative to 
control animals, demonstrating a role for IDE in regulating the abundance of these hormones 
(Figs. 3.4b to 3.4d insets).   
 
3.8 IDE inhibition promotes glucagon signaling and gluconeogenesis 
 Taken together, these results strongly suggest that IDE activity regulates the stability and 
physiological activities of glucagon and amylin, in addition to insulin.  Higher glucagon levels 
upon 6bK treatment provide a possible explanation for impaired glucose tolerance observed 
during an IPGTT.  This model predicts that abrogating glucagon signaling should reverse the 
elevation of blood glucose by 6bK treatment during an IPGTT, while not substantially affecting 
the signaling pathways through which 6bK treatment lowers blood glucose during an OGTT.   
 To explicitly test these hypotheses, we repeated the glucose tolerance experiments using 
GCGR–/– mice that lack the G-protein coupled glucagon receptor (Fig. 3.5a and 3.5b)44.  As 
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expected, mice lacking glucagon signaling exhibited an improvement in oral glucose tolerance 
upon 6bK treatment relative to vehicle controls that was similar to the oral glucose tolerance 
improvement observed in wild-type mice (Fig. 3.5a), consistent with a model in which insulin 
signaling in these mice is intact and regulated by IDE.  In contrast, the responses of GCGR–/– 
mice treated with 6bK or vehicle alone to i.p. injected glucose were virtually identical, consistent 
with a model in which glucagon signaling drives the impaired glucose tolerance of wild-type lean 
and DIO mice upon 6bK treatment during an IPGTT (compare Figs. 3.5b and 3.3c).  
Collectively, these results reveal that IDE inhibition promotes glucagon signaling that can impair 
glucose tolerance during an IPGTT.  
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Figure 3.5 Acute IDE inhibition modulates the endogenous signaling activity of glucagon, 
amylin and insulin.  a and b, G-protein-coupled glucagon receptor knockout mice (GCGR–/–, 
C57BL/6J background) treated with IDE inhibitor 6bK (, 80 mg/kg) display altered glucose 
tolerance relative to vehicle-treated mice () if challenged with oral glucose (a) but not i.p. 
injected glucose (b).  c, Wild-type mice fasted overnight were injected i.p. with pyruvate (2.0 
g/kg) 30 min after treatment with 6bK (), inactive analog bisepi-6bK (), or vehicle alone ().  
d, Plasma hormone measurements 60 min post-PTT reveal elevated glucagon but similar 
insulin levels for the 6bK-treated cohort () relative to bisepi-6bK (), or vehicle () controls.  
e, RT-PCR analysis of liver samples 60-min post-PTT revealed elevated gluconeogenesis 
transcriptional markers for the 6bK-treated group () relative to vehicle controls ().  f, Acute 
IDE inhibition slows gastric emptying through amylin signaling.  Wild-type mice fasted overnight 
were given an oral glucose bolus (3.0 g/kg supplemented with 0.1 mg/mL phenol red) 30 min 
after treatment with 6bK alone (), 6bK co-administered with the specific amylin receptor 
antagonist AC187 (, 3 mg/kg i.p.), vehicle alone (), or inactive bisepi-6bK ().  The 
stomachs were dissected at 30 min post-glucose gavage.  All data points and error bars 
represent mean ± SEM.  Significance tests were performed using two-tail Student’s t-test, and 
significance levels shown are p < 0.05 (*) or p < 0.01 (**) versus the vehicle-only control group.   
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  To investigate the effect of IDE inhibition on endogenously secreted glucagon, we 
subjected mice treated with 6bK, vehicle, or inactive bisepi-6bK to a pyruvate tolerance test 
(PTT), which measures the ability of the liver under the action of glucagon to use pyruvate as a 
gluconeogenic substrate (Fig. 3.5c).  The 6bK-treated cohort displayed significantly elevated 
plasma glucagon and increased expression of liver gluconeogenic markers compared to both 
control groups (Figs. 3.5d and 3.5e).  The 6bK cohort also experienced significantly lower blood 
glucose during the PTT, suggesting that IDE inhibition produced a concomitant stimulation of 
glucose clearance that outweighed its effects on gluconeogenesis (Fig. 3.5c).  These results 
collectively establish that IDE inhibition can augment endogenous glucagon signaling under 
conditions that favor gluconeogenesis. 
 
3.9 IDE inhibition promotes amylin signaling and gastric emptying 
 Amylin is co-secreted with insulin, and is involved in glycemic control by inhibiting gastric 
emptying through the vagal route45, promoting satiety during meals46, and antagonizing 
glucagon signaling47.  Pramlintide (Smylin) is a synthetic amylin derivative used clinically to 
control post-prandial glucose levels33,36,48.  To determine the effects of IDE inhibition on 
endogenous amylin signaling, we measured gastric emptying efficiency49, an amylin-specific 
process, in mice treated with 6bK, inactive control bisepi-6bK, or vehicle alone.  Mice treated 
with 6bK exhibited 2-fold slower gastric emptying of a labeled glucose solution measured at 30 
minutes post-gavage compared to vehicle and bisepi-6bK-treated controls (Fig. 3.5f).  
Importantly, co-administration of the specific amylin receptor antagonist AC18750 blocked the 
effects of 6bK on gastric emptying (Fig. 3.5f).  Collectively, these data reveal that IDE inhibition 
can slow post-prandial gastric emptying and demonstrate a role for IDE in modulating amylin 
signaling in vivo.  These results also suggest that IDE inhibition may mimic the effect of amylin 
supplementation with pramlintide during meals2,33. 
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3.10 Implications  
 The discovery and application of the first potent, highly selective, and physiologically 
active small-molecule IDE inhibitor revealed that acute IDE inhibition can lead to improved 
glucose tolerance in lean and obese mice after oral glucose administration, conditions that 
mimic the intake of a meal.  These results validate the potential of IDE as a therapeutic target 
following decades of speculation3,4.  Our data show that small-molecule IDE inhibitors can 
improve oral glucose tolerance to an extent comparable to that of DPP4 inhibitors2,33.  The 
potential relevance of these animal studies to human disease is supported by the repeated 
recognition of IDE as a diabetes susceptibility gene in humans5-11.    
 Equally important, additional in vivo and biochemical experiments using 6bK led to the 
discovery that IDE regulates the stability and signaling of glucagon and amylin, in addition to its 
established role in insulin degradation10-12.  The identification of two additional pancreatic 
hormones as endogenous IDE substrates advances our understanding of the role of IDE in 
regulating physiological glucose homeostasis (Fig. 3.6).  Amylin-mediated effects on gastric 
emptying and satiety during meals have been recently recognized to have therapeutic relevance 
in the treatment of diabetes2,33, and our results represent the first demonstration of a small-
molecule that can regulate both amylin and insulin signaling.  Moreover, the link between IDE 
and glucagon revealed in this study provides additional evidence of the importance of glucagon 
regulation in human diabetes51. 
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Figure 3.6 Model for the expanded roles of IDE in glucose homeostasis and gastric 
emptying based on the results of this study.  IDE inhibition increases the abundance and 
signaling of three key pancreatic peptidic hormones, insulin, amylin, and glucagon, with the 
corresponding physiological effects shown in blue and red. 
 
 Our study also reveals a specific pharmacological requirement for therapeutic IDE 
inhibition—namely, that transient, rather than chronic, IDE inhibition is desirable to prevent 
elevation of glucagon signaling51 (Fig. 3.6).  A potential anti-diabetic therapeutic strategy 
motivated by these findings is the development of a fast-acting IDE inhibitor that can be taken 
with a meal to transiently augment endogenous insulin and amylin responses to help control 
post-prandial glycemia33,34, and that is cleared or degraded before glucagon secretion resumes.  
Similar pre-meal therapeutic strategies with short-lived agents have already proven successful 
with fast-acting insulin analogs, secretagogues, and amylin supplementation34,35.  It is tempting 
to speculate these agents may also have synergistic effects when co-administered with an IDE 
inhibitor3,52.  Alternatively, the combination of an IDE inhibitor with incretin therapy2,33 or a 
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glucagon receptor antagonist51, may also prove therapeutic, as suggested by our experiments 
with glucagon-receptor deficient mice.  Our findings also raise the possibility that future 
generations of IDE modulators may achieve substrate-selective inhibition13 to enable the 
selective degradation of substrates such as glucagon while impairing the degradation of insulin.   
 The identification of a highly selective IDE inhibitor using a DNA-encoded library coupled 
with in vitro selection further establishes the value of this approach for the target-based 
discovery of bioactive small molecules.  The unbiased nature of the selection led to the 
identification of a novel small-molecule binding site in IDE that enables unprecedented inhibition 
selectivity for this enzyme.  These macrocycles and structural insights therefore may also prove 
useful in the development of assays that specifically target this binding site, and in the discovery 
of novel therapeutic leads that target IDE inhibition.  More generally, this work highlights the 
value of physiologically active small-molecule probes to characterize the functions of genes 
implicated in human disease, an approach that could prove increasingly valuable as human 
genomic studies become more prevalent15,16. 
 
3.11 Methods  
In vitro selection of a DNA-templated library with immobilized mouse IDE.  The in 
vitro selection used here was adapted from previously described protocols1,2 using a DNA-
templated library of 13,824 macrocycles3. Recombinant N-His6-tagged mouse IDE42-1019 (isoform 
containing the amino acids 42-1019 of the IDE sequence) was purified using immobilized cobalt 
magnetic beads (Dynabeads® His-Tag Isolation & Pulldown, Invitrogen®) according to the 
manufacturer’s instructions. This purified IDE was confirmed to be catalytically active using the 
peptide substrate assay described below.  IDE protein (~20 µg) was loaded onto the solid 
support by incubating the protein with beads (30 µL) at 25 °C for 30 min in 300 µL of pH 8.0 
buffer containing 50 mM phosphate, 300 mM NaCl and 0.01 % Tween-20 (PBST buffer), and 
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washed twice with the same buffer.  Two individually prepared protein-bead suspensions were 
incubated for 30 min with 5 pmol of the DNA-templated macrocycle library at RT, in pH 7.4 
buffer containing 50 mM Tris-HCl, 150 mM NaCl, 0.05 % Tween-20 (TBST buffer) 
supplemented with 0.01 % BSA and 3 mg/mL yeast RNA (Ambion®).  The beads were washed 
three times with 200 µL TBST buffer.  The enriched library fraction was eluted by treatment with 
200 mM imidazole in PBST buffer (50 µL) for 5 min.  
The eluate solution was isolated and purified by buffer exchange using Sephadex spin-
columns (Centrisep, Princeton Separation), according to the manufacturer’s instructions.  PCR 
amplification of the enriched pool of library barcodes was performed as previously reported1, 
using primers that append adaptors for Illumina sequencing and a 7-base identifier.  The long 
adaptor primer was 
5’_AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC 
TCTTCCGATCTXXXXXXCCCTGTACAC and the short adaptor primer was 5’_CAAGCAG 
AAGACGGCATACGAGCTCTTCCGATCTGAGTGGGATG (the 7-base identifier was XXXXXX).  
The PCR amplicons were purified by polyacrylamide gel electrophoresis, extracted, and 
quantified using qPCR and Picogreen assays (Invitrogen).  
High-throughput DNA sequencing was performed on an Illumina Genome Analyzer 
instrument at the Harvard FAS Center for Systems Biology, Cambridge, MA, to yield an average 
of ~3.8 million sequence reads for each selection, untreated bead control and pre-selection 
library. Deconvolution of library barcodes and enrichment calculations were performed with 
custom software as described previously1.  Variations in library member abundance as a result 
of binding to immobilized IDE was revealed by calculating fold-enrichment over the pre-selection 
library for the two independent selection experiments (Extended Data Fig. 1). 
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Protease assays with fluorogenic peptide substrates.  The proteases IDE42-1019, 
recombinant human IDE42-1019 (R&D Systems), neprilysin (R&D), and angiotensin-converting 
enzyme (R&D) were assayed using the fluorophore/quencher-tagged peptide substrate Mca-
RPPGFSAFK(Dnp)-OH (R&D) according to the manufacturer’s instructions and recommended 
buffers.  For IDE the recommended buffer is 50 mM Tris pH 7.5, 1 M NaCl.  The enzyme 
mixtures (48 µL) were transferred to a 96-well plate and combined with 2 µL of inhibitor in 
DMSO solutions, in 3-fold dilution series.  The mixtures were allowed to equilibrate for 10 min 
and the enzymatic reaction was started by addition of substrate peptide in assay buffer (50 µL), 
mixed, and monitored on a fluorescence plate reader (excitation at 320 nm, emission at 405 
nm).  Similarly, thimet oligopeptidase (R&D) and neurolysin (R&D) were assayed using 
substrate Mca-PLGPK(Dnp)-OH (R&D) according to the manufacturer’s instructions and 
recommended buffers.  Matrix metalloproteinase-1 (R&D) was activated and assayed according 
to the manufacturer’s instructions with substrate Mca-KPLGL-Dpa-AR-NH2 (R&D). All assay 
data points were obtained in duplicate. Data for the Yonetani–Theorell double inhibition plot was 
generated using 1 µL of each inhibitor (6b, and Ii1 or bacitracin) under otherwise identical 
conditions as above, at concentrations corresponding to ⅓x, 1x, 3x and 9x of respective IC50 
values against hIDE (R&D).4,5 
 
Protease assays with fluorogenic peptide substrates.IDE degradation assays for 
insulin and calcitonin-gene related peptide (CGRP).  A solution of 0.4 µg/mL IDE (R&D) in 
pH 7.5 buffer containing 50 mM Tris, 1.0 M NaCl (48 µL) was transferred to a 96-well plate, and 
combined with 2 µL of each inhibitor (6b, 6bK and 28) dissolved in DMSO, in 3-fold dilution 
series (Extended Data Fig. 2c).  A solution of insulin (50 µL) was added to a final concentration 
of 10 ng/mL, and incubated at 30 °C for 15 min.  This procedure was optimized to result in ~75 
% degradation of insulin.  The reaction was terminated by addition of inhibitor 6bK to a final 
71 
 
concentration of 20 µM and chilled on ice.  Insulin was quantified using 10 µL of the enzymatic 
reaction for the sensitive-range protocol Homogeneous Time-Resolved FRET Insulin assay 
(CysBio®) in 20 µL total volume according to the manufacturer’s instructions.  Fluorescence 
was measured using a Tecan Safire 2 plate reader (excitation = 320 nm, emission = 665 and 
620 nm, lag time = 60 µs) according the assay manufacturer’s recommendations.  Degradation 
of CGRP by endogenous IDE in mouse plasma was analyzed by LC-MS for the formation of 
CGRP1-17 and CGRP18-37 as previously reported
6.  The substrate was added to a final 
concentration of 10 µM, and 6b was added to a final concentration of 0.1 to 10 µM (Extended 
Data Fig. 2d). 
 
General procedure for synthesis of macrocycle inhibitors.  Rink amide resin 
(NovaPEG Novabiochem®, ~0.49 mmol/g, typically at a scale of 0.1 to 2 mmol) was swollen 
with ~10 volumes of anhydrous DMF for 1 h in a peptide synthesis vessel with mixing provided 
by dry nitrogen bubbling.  In a separate flask, Nα-allyloxycarbonyl-Nε-2-Fmoc-L-lysine (5 equiv.) 
and 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate (HATU, 
4.75 equiv.) were dissolved in anhydrous DMF (~10 vol.), then treated with N,N'-
diisopropylethylamine (DIPEA, 10 equiv.) for 5 min at RT.  The solution was combined with the 
pre-swollen Rink amide resin and mixed with nitrogen bubbling overnight.  The vessel was 
eluted and the resin was washed three times with N-methyl-2-pyrrolidone (NMP, ~10 vol.).  
Following each coupling step, Fmoc deprotection was effected with 20 % piperidine in NMP 
(~20 vol.) for 20 min, repeated three times, followed by washing three times with NMP (~10 vol.) 
and twice with anhydrous DMF (~10 vol.).  The general procedure for amide coupling of building 
blocks A, B and C was treatment of the resin with solutions of HATU-activated Nα-Fmoc amino 
acids (5 equiv.) for 3-5 hours in anhydrous DMF, mixing with dry nitrogen bubbling.  The general 
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procedure for HATU-activation was treating a solution of Nα-Fmoc amino acid (5 equiv.) and 
HATU (4.75 equiv.) in anhydrous DMF (10 vol.) with DIPEA (10 equiv.) for 5 min at RT.  
Following the final Fmoc deprotection procedure, the α-amine of building block C was 
coupled with allyl fumarate monoester (10 equiv.) using activation conditions as previously 
described with HATU (9.5 equiv.) and DIPEA (20 equiv.) in anhydrous DMF (~10 vol.).  Allyl 
fumarate coupling was accomplished by overnight mixing with dry nitrogen bubbling, followed by 
washing five times with NMP (~10 vol.) and three times with CHCl3 (~10 vol.).  Simultaneous 
allyl ester and N-allyloxycarbonyl group cleavage in solid support was effected with three 
consecutive treatments with a solution of tetrakis(triphenylphosphine)palladium(0) (0.5 equiv.) 
dissolved in degassed CHCl3 containing acetic acid and N-methylmorpholine (40:2:1 ratio, ~20 
vol.), mixing by nitrogen bubbling for 30 min.  The resin was then washed twice subsequently 
with ~20 vol. of 5 % DIPEA in DMF, then twice with a 5 % solution of sodium 
diethyldithiocarbamate trihydrate in DMF (~20 vol.), twice with 5 % solution of 
hydroxybenzotriazole monohydrate in DMF, and finally washed with 50 % CH2Cl2 in DMF and 
re-equilibrated with anhydrous DMF (~10 vol.).  
Treating the resin with pentafluorophenyl diphenylphosphinate (5 equiv.) and DIPEA (10 
equiv.) in anhydrous DMF (~10 vol.) mixing by nitrogen bubbling overnight produced the 
macrocyclized products.  The resin was washed with NMP (~20 vol.) and CH2Cl2 (~20 vol.) and 
dried by vacuum.  The macrocyclized product was cleaved from the resin by two 15 min 
treatments of the macrocycle-bound resin with 95 % TFA containing 2.5 % water and 2.5 % 
triisopropylsilane (~20 vol.), followed by two TFA washes (~5 vol.).  The TFA solution was dried 
to a residue under rotatory evaporation, and the peptide was precipitated by the addition of dry 
Et2O.  The ether was decanted and the remaining solid was dried and dissolved in a minimum 
volume of 3:1 DMF-water prior to purification by liquid chromatography.  HPLC purification was 
performed on a C18 21.2x250 mm column (5 µm particle, 100 Å pore size, Kromasil®), using a 
gradient of 30 % to 80 % MeCN/water over 30 min, and solvents containing 0.1 % TFA.  
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Fractions containing the desired macrocyclic peptide were combined and freeze-dried to 
produce a white powder.  Typical yields were 5-15 % based on resin loading.  Purity was 
determined by HPLC (Zorbax SB-C18 2.1x150 mm column, 5 µm particle) with UV detection at 
230 nm, using a gradient of 30 % to 80 % MeCN/water over 30 min, and solvents containing 0.1 
% TFA.  The formula of final products was confirmed by accurate mass measurements using an 
Agilent 1100 LC-MSD SL instrument (Supplementary Table S2). 
Dosing and formulation of macrocycle inhibitors for in vivo studies. The doses of 6bK 
used in this study were chosen based on literature precedent for small molecules and drugs of 
similar potencies7-13.  Procedures using experimental compounds were in accordance with the 
standing committee on the Use of Animals in Research and Teaching at Harvard University, the 
guidelines and rules established by the Faculty of Arts and Sciences' Institutional Animal Care 
and Use Committee (IACUC), and the National Institutes of Health Guidelines for the Humane 
Treatment of Laboratory Animals. 
Purified macrocycle inhibitors were dissolved in DMSO-d6 (~200 to 250 mg/mL stock 
solutions).  A sample aliquot (5 µL) of the macrocycle solution was diluted with 445 µL DMSO-
d6, then combined with 50 µL of freshly prepared solution of 20 mM CH2Cl2 in DMSO-d6 in for 
1H-NMR acquisition (600 MHz, relaxation time = 2 sec).  The inhibitor concentration was 
calculated using the integral of the CH2Cl2 singlet (δ 5.76 ppm, 2H)
14, which appears in an 
uncluttered region of these spectra1,15.  For injectable formulations (10 mL/kg i.p. injection 
volume), the macrocycle inhibitor solution in DMSO-d6 (200 – 250 mg/mL, based on free-base 
molecular weight) was combined with 1:20 w/w Captisol® powder (CyDex)16.  The resulting 
slurry was supplemented with DMSO-d6 to make up to 5 % of the final formulation volume, 
mixed thoroughly and dissolved with sterile saline solution (0.9 % NaCl).  Vehicle controls were 
identically formulated with 5 % DMSO-d6 and equal amount of Captisol®.  The formulated 
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solutions of inhibitor were clear with no visible particles, and were stored overnight at 4 °C prior 
to injection. 
 
Expression and purification of recombinant cysteine-free hIDE (IDE-CF).  We 
expressed cysteine-free catalytically-inactive, human IDE (IDE-CF) in pPROEX vector17.  IDE-
CF contains the following substitutions: C110L, E111Q, C171S, C178A, C257V, C414L, C573N, 
C590S, C789S, C812A, C819A, C904S, C966N, and C974A.  IDE was expressed and purified 
as previously described17.  Briefly, IDE-CF was transformed into E. coli BL21-CodonPlus (DE3)-
RIL, grown at 37 °C to a cell density of 0.6 O.D. and induced with IPTG at 16 °C for 19 hours.  
Cells were lysed and the lysate was subjected to Ni-affinity (GE LifeScience) and anion 
exchange chromatography (GE LifeScience). The protein was further purified by size exclusion 
chromatography (Superdex S200 column) three successive times, first without inhibitor then two 
times after addition of 2-fold molar excess of 6b. 
 
IDE-CF•6b co-crystallization.  Eluent from size exclusion chromatography was 
concentrated to 20 mg/ml in 20 mM Tris, pH 8.0, 50 mM NaCl, 0.1 mM PMSF and 2-fold molar 
excess of 6b was added to form the protein-inhibitor complex.  The complex was mixed with 
equal volumes of reservoir solution containing 0.1 M HEPES (pH 7.5), 20 % (w/v) PEGMME-
5000, 12 % tacsimate and 10 % dioxane.  Crystals appeared after 3-5 days at 25 °C and were 
then equilibrated in cryoprotective buffer containing well solution and 30 % glycerol.  IDE-CF•6b 
complex crystals belong to the space group P65, with unit-cell dimensions a = b = 262 Å and c = 
90 Å, and contain two molecules of IDE per asymmetric unit (Extended Data Figure 3a).  
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X-Ray Diffraction. X-ray diffraction data were collected at the National Synchrotron 
Light Source at Brookhaven National Laboratories beamline X29 at 100K and 1.075 Å. 
 
IDE-CF•6b structure determination. Data were processed in space group P65 using 
autoProc18.  The structure was phased by molecular replacement using the structure for human 
IDE E111Q (residues 45-1011, with residues 965-977 missing) in complex with inhibitor 
compound 41367 (PDB: 2YPU) as a search model in Phaser19.  The model of the structure was 
built in Coot20 and refined in PHENIX21, using NCS (torsion-angle) and TLS (9 groups per 
chain).  In the Ramachandran plot, 100 % of the residues appear in the allowed regions, 97.2 % 
of the residues appear in the favored regions, and 0 % of the residues appear in the outlier 
regions (Extended Data Figure 3a).  The structural model of IDE and inhibitor was refined using 
non-crystallographic symmetry restraints due to the high degree of structural similarity between 
the two chains of the protein the asymmetric unit. The root-mean-square deviation between the 
two chains is 0.5 Å for the protein chains, and 0.9 Å for the ligand atoms, indicating high 
structural similarity between the two chains. Structure coordinates are deposited in the Protein 
Data Bank (accession number 4TLE). 
 
Macrocycle docking simulations.  Receptor and ligand preparation was performed in 
the standard method22,23.  DOCKing was performed using version 6.6 with default parameters 
for flexible ligand and grid-based scoring, and the van der Waals exponent was 9.  Because of 
the mutagenesis data strongly pointing to a role of Ala479, we limited docking of the macrocycle 
to an area within 15 Å of Ala479.  The highest scoring poses (Extended Data Fig. 3), by both 
gridscore5 and Hawkins GB/SA6, are consistent with the placement of building blocks A 
(benzophenone), B (cyclohexyl ring), and trans olefin of 6b in the proposed structure.  Docking 
calculations for the inactive isomer 6a were unsuccessful, while for the low-activity analog 11 
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the result was a different and lower-scoring pose than 6b, consistent with the mutagenesis and 
biochemical assay results (Table S5, Fig. 1b, Extended Data Fig. 4). 
 
Anisotropy binding assay.  Catalytically-inactive CF-IDE was titrated with fluorescein-
labeled macrocycle 31 in 20 mM Tris buffer pH 8.0, with 50 mM NaCl, and 0.1 mM PMSF at 
25°C in the presence or absence of insulin (2.15 µM).  The final assay volume was 220 µL, with 
a final DMSO concentration of 0.1 % and a final 31 concentration of 0.9 nM.  After equilibration, 
the increase in the fluorescence anisotropy of the fluorescent ligand was recorded at 492 nm, 
using excitation at 523 nm, and fitted against a quadratic binding equation in Kaleidagraph 
(Synergy Software) to yield the dissociation constant (KD = 43 nM).  From our structural work, 
we hypothesized that insulin and macrocycle 31 compete for the same binding site. 
Equation 124 approximates how the concentration of insulin ([I]) and the affinity constant 
of insulin (Ki = 280 nM) affect the apparent dissociation constant (KD
app) of macrocycle 31 for 
CF-IDE.  In the absence of competing insulin, 31 binds with the dissociation constant (KD = 43 
nM) to CF-IDE.  In the presence of 2.15 uM insulin, the calculated KD
app for macrocycle 31 is 
363 nM (~8-fold shift) which is in good agreement with the competitive binding mode revealed 
by the crystal structure, and the anisotropy measurements (observed ~7-fold shift, KD
app= ~ 280 
nM, Extended Data Fig. 3e). 
 
 
Eq. 1 
Site-directed mutagenesis, expression, and purification of human IDE.  The 
reported N-His6-tagged human IDE42-1019 construct was introduced in the expression plasmid 
pTrcHis-A (Invitrogen) using primers for uracil-specific excision reactions (USER) by Taq (NEB) 
and Pfu polymerases (PfuTurbo CX®, Agilent).  The IDE gene was amplified with the primers 5’-
KD
app  =     1 +
[ I ]
Ki
. KD
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ATCATCATATGAATAATCCAGCCA-dU-CAAGAGAATAGG and 5’-
ATGCTAGCCATACCTCAGA G-dU-TTTGCAGCCATGAAG (underlined sequences represent 
overhangs, and italics highlight the PCR priming sequence).  Similarly, the pTrcHis-A vector 
was amplified for USER cloning with the primers 5’-ATGGCTGGATTATTCATATGATGA-dU-
GATGATGATGAGAACCC and 5’-ACTCTGAGGTATGGCTAGCA-dU-GACTGGTG.  Mutant 
IDE constructs were generated by amplifying the full vector construct with USER cloning 
primers introducing a mutant overhang (Supplementary Table S3). 
All PCR products were purified on microcentrifuge membrane columns (MinElute®, 
Quiagen) and quantified by UV absorbance (NanoDrop).  Each fragment (0.2 pmol) was 
combined in a 10 µL reaction mixture containing 20 units DpnI (NEB), 0.75 units of USER mix 
(Endonuclease VIII and Uracil-DNA Glycosylase, NEB), 20 mM Tris-acetate, 50 mM potassium 
acetate, 10 mM magnesium acetate, 1 mM dithiothreitol at pH 7.9 (1x NEBuffer 4).  The 
reactions were incubated at 37 °C for 45 min, followed by heating to 80 °C and slow cooling to 
30 °C (0.2 °C/s).  The hybridized constructs were directly used for heat-shock transformation of 
chemically competent NEB turbo E. coli cells according to the manufacturer’s instructions.  
Transformants were selected on carbenicillin LB agar, and isolated colonies were cultured 
overnight in 2 mL LB.  
The plasmid was extracted using a microcentrifuge membrane column kit (Miniprep®, 
Qiagen), and the sequence of genes and vector junctions were confirmed by Sanger 
sequencing (Supplementary Table S4).  The plasmid constructs were transformed by heat-
shock into chemically-competent expression strain Rosetta 2 (DE3) pLysS E. coli cells (EMD 
Millipore), and selected on carbenicillin/chloramphenicol LB agar.  Cells transformed with IDE 
pTrcHis A constructs were cultured overnight at 37 °C in 2 XYT media (31 g in 1L) containing 
100 μg/mL ampicillin and 34 μg/mL chloramphenicol.  Expression of His6-tagged IDE proteins 
was induced when the culture measured OD600 ~0.6 by addition of isopropyl-β-D-1-
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thiogalactopyranoside (IPTG) to 1 mM final concentration, incubated overnight at 37 °C, 
followed by centrifugation at 10,000 g for 30 min at 4 °C.  
Recombinant His6-tagged proteins were purified by Ni(II)-affinity chromatography (IMAC 
sepharose beads, GE Healthcare®) according to the manufacturer’s instructions.  The cell 
pellets were resuspended in pH 8.0 buffer containing 50 mM phosphate, 300 mM NaCl, 10 mM 
imidazole, 1 % Triton X-100 and 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP), and 
were lysed by probe sonication for 4 min at <4 °C, followed by clearing of cell debris by 
centrifugation at 10,000 g for 25 min at 4 °C.  The supernatant was incubated with Ni(II)-doped 
IMAC resin (2 mL) for 3 h at 4 °C.  The resin was washed twice with the cell resuspension/lysis 
buffer, and three times with pH 8.0 buffer containing 50 mM phosphate, 300 mM NaCl, 50 mM 
imidazole and 1 mM TCEP.  Elution was performed in 2 mL aliquots by raising the imidazole 
concentration to 250 mM and subsequently to 500 mM in the previous buffer.  The fractions 
were combined and the buffer was exchanged to the recommended IDE buffer (R&D) using spin 
columns with 100 KDa molecular weight cut off membranes (Millipore).  Protein yields were 
typically ~10 µg/L, and >90 % purity based on gel electrophoresis analysis (Coomassie stained).  
IDE-specific protease activity was >95 % as assessed by inhibition of degradation of peptide 
substrate Mca-RPPGFSAFK(Dnp)-OH (R&D) by 20 µM 6bK, compared with pre-quantitated 
commercially available human IDE (R&D). The complete list of IDE mutations assayed is shown 
in Supplementary Table S5.  
 
In vivo studies, general information.  Wild-type C57BL/6J and diet-induced obese 
(DIO) C57BL/6J age-matched male adult mice were purchased from Jackson Laboratories.  The 
age range was 13 to 15 weeks for lean mice, and 24 to 26 weeks for DIO mice.  All animals 
were individually housed on a 14-h light, 10-h dark schedule at the Biology Research 
Infrastructure (BRI), Harvard University.  Cage enrichment included cotton bedding and a red 
plastic hut.  Water and food were available ad libitum, consisting respectively of normal chow 
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(Prolab® RHM 3000) or high-fat diet (60 kcal % fat, D12492, Research Diets Inc.).  Adult IDE 
knock-out mice (IDE–/–) and control mice (IDE+/+) were obtained from Mayo Clinic (Florida), and 
housed in the Biology Research Infrastructure (BRI), Harvard University, for 8 weeks prior to 
experiments as described above.  Experiments were conducted on IDE–/– and +/+ age-matched 
mice cohorts ranging 17 to 21 weeks old.  All animal care and experimental procedures were in 
accordance with the standing committee on the Use of Animals in Research and Teaching at 
Harvard University, the guidelines and rules established by the Faculty of Arts and Sciences' 
Institutional Animal Care and Use Committee (IACUC), and the National Institutes of Health 
Guidelines for the Humane Treatment of Laboratory Animals.  Glucagon-receptor knock-out 
mice (GCGR–/–) and control WT mice (GCGR+/+) were group-housed with a 14-h light and 10-h 
dark schedule and treated in accordance with the guidelines and rules approved by the IACUC 
at Albert Einstein College of Medicine, NY. Power analysis to determine animal cohort numbers 
was based on preliminary results and literature precedent, usually requiring between 5 and 8 
animals per group. Animals were only excluded from the cohorts in cases of chronic weakness, 
which occurs among GCGR–/– mice, or when we identified occasional DIO mice with an outlier 
diabetic phenotype (e.g. >200 mg/dL fasting blood glucose). Age- and weight-matched mice 
were randomized to each treatment group. Double-blinding was not feasible. 
 
Glucose tolerance tests GTT and blood glucose measurements.  Prior to a glucose 
challenge, the animals were fasted for 14 h (8 pm to 10 am, during the dark cycle) while 
individually housed in a clean cage with inedible wood-chip as a floor substrate, cotton bedding 
and a red plastic hut.  Inhibitor, vehicle or control compounds were administered by a single 
intraperitoneal (i.p.) injection 30 min prior to the glucose challenge.  Dextrose was formulated in 
sterile saline (3 g in 10 mL total), and the dose was adjusted by fasted body weight.  For oGTT, 
3.0 g/kg dextrose was administered by gavage at a dose of 10 mL/kg, and for ipGTT, 1.5 g/kg 
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dextrose injected at a dose of 5 mL/kg.  Blood glucose was measured using AccuCheck® 
meters (Aviva) from blood droplets obtained from a small nick at the tip of the tail, at timepoints -
45, 0, 15, 30, 45, 60, 90 and 120 min with reference to the time of glucose injection.  The area 
of the blood glucose response profile curve corresponding to each animal was calculated by the 
trapezoid method25, using as reference each individual baseline blood glucose measurement 
prior to glucose administration (t = 0).  The sum of the trapezoidal areas between the 0, 15, 30, 
45, 60, 90 and 120 minute time points corresponding to each animal were summed to obtain the 
area under the curve (AUC).  The relative area values are expressed as a percentage relative to 
the average AUC of the vehicle cohort, which is defined as 100 % (Extended Data Fig 9).  
Values are reported as mean ± S.E.M.  Statistics were performed using a two-tail Student’s t-
test, and significance levels shown in the figures are * p < 0.05 versus vehicle control group or 
** p < 0.01 versus vehicle control group. 
 
Insulin Tolerance Test (ITT), Glucagon Challenge (GC) and Amylin Challenge (AC) 
For hormone challenges animals were fasted individually housed as described above.  For ITT 
the fasting period was 6 h (7 am to 1 pm), and for glucagon and amylin challenges the fasting 
period was 14 h (8 pm – 10 am).  Inhibitor or vehicle alone was injected i.p. as previously 
described, 30 min prior to each hormone challenge.  Insulin (Humulin-R®, Eli Lilly) was injected 
subcutaneously (s.c.) 0.25 U/kg formulated in sterile saline (5 mL/kg).  Glucagon (Eli Lilly) was 
injected s.c. 100 µg/kg formulated in 0.5 % BSA sterile saline (5 mL/kg).  Amylin (Bachem) was 
injected s.c. 250 µg/kg formulated in sterile saline (5 mL/kg).  Blood glucose was measured at 
timepoints -45, 0, 15, 30, 45, 60 and 75 min with reference to the time of hormone injection, by 
microsampling from a tail nick as described above.  Values are reported as mean ± S.E.M.  
Statistics were performed using a two-tail Student’s t-test, and significance levels shown in the 
figures are * p < 0.05 versus vehicle control group or ** p < 0.01 versus vehicle control group. 
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Blood collection and plasma hormone measurements.  Blood was collected in 
EDTA-coated tubes (BD Microtainer®) from trunk bleeding (~500 µL) after CO2-euthanasia for 
all hormone assays.  The plasma was immediately separated from red blood cells by 
centrifugation 10 min at 1800 g, aliquoted, frozen over dry ice and stored at -80 °C.  Insulin, 
glucagon, amylin and pro-insulin C-peptide fragment were quantified from 10 µL plasma 
samples using magnetic-bead Multiplexed Mouse Metabolic Hormone panel (Milliplex, EMD 
Millipore) according to the manufacturer’s instructions, using a Luminex FlexMap 3D instrument.  
Plasma containing high levels of human insulin (Humulin-R) were quantified using 25 µL 
samples with Insulin Ultrasensitive ELISA (ALPCO).  Values are reported as mean ± S.E.M.  
Statistics were performed using a two-tail Student’s t-test, and significance levels shown in the 
figures are * p < 0.05 versus vehicle control group or ** p < 0.01 versus vehicle control group. 
 
Gastric emptying measurements.  Mice were fasted 14 h (8 pm to 10 am).  Inhibitor or 
vehicle alone was injected i.p. as previously described, followed 30 min later by an oral glucose 
bolus (3.0 g/kg, 10 mL/kg) in sterile saline containing 0.1 mg/mL phenol red.  At 30 min, the 
stomach was promptly dissected after CO2-euthanasia and stored on ice.  The stomach 
contents were extracted into 2.5 mL EtOH (95 %) by homogenization for 1 min using a probe 
sonicator.  Tissue debris were decanted by centrifugation at 4000 g, followed by clearing at 
15000 g for 15 min.  The supernatant (1 mL) was mixed with 0.5 mL of aqueous NaOH (20 
mM), and incubated at -20 °C for 1 h.  The solution was centrifuged at 15,000 g for 15 min, and 
absorbance was determined at 565 nM.  The spectrophotometer was blanked with the stomach 
contents of a mouse treated with colorless glucose solution.  The absorbance was adjusted to 
the amount of glucose solution dosed to each mouse.  Values are reported as mean ± S.E.M 
relative to the original phenol red glucose solution.  Statistics were performed using a two-tail 
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Student’s t-test, and significance levels shown in the figures are * p < 0.05 versus vehicle 
control group or ** p < 0.01 versus vehicle control group. 
 
Stable isotope dilution LC-MS, pharmacokinetics, and tissue distribution 
measurements.  Heavy-labeled macrocycle inhibitor (heavy-6bK, Extended Data Fig. 5) was 
synthesized as described above, substituting “building block C” with Nα-Fmoc-Nε-Boc-lysine 13C6 
15N2 (98 atom %, Sigma-Aldrich).  The product was 8 mass-units heavier than 6bK, otherwise 
with identical properties and IC50.  Plasma samples (15 µL) from 6bK-treated mice and vehicle 
controls were combined with 5 µL of heavy-6bK in PBS (final concentration of 10 µM), and 
incubated for 30 min on ice.  Plasma proteins were precipitated with 180 µL cold 1 % TFA in 
MeCN, sonicated 2 min, and centrifuged 13,000 g for 1 min.  The supernatant was diluted 100- 
and 1000-fold for liquid chromatography-mass spectrometry (LC-MS) analysis.  Tissue samples 
(~100 mg) from 6bK-treated mice and vehicle controls were weighed and disrupted in Dounce 
homogenizers with PBS buffer (0.5 mL/100 mg sample), supplemented with 5 µM heavy-6bK 
and protease inhibitor cocktail (1 tablet/50 mL PBS, Roche diagnostics).  The lysate was 
incubated on ice for 30 min, sonicated 5 min and centrifuged at 13,000 g for 5 min.  The bulk of 
supernatant proteins were precipitated by denaturation at 95 °C for 5 min, removed by 
centrifugation.  A 50 µL aliquot of the supernatant was treated with 450 µL cold 1 % TFA in 
MeCN, cleared by centrifugation and diluted 100-fold for LC-MS analysis as described above for 
plasma samples.  A standard curve of 6bK and heavy-6bK (1 µM each and 3-fold serial 
dilutions) were used for LC-MS quantitation using a Waters Q-TOF premier instrument. 
 
RT-PCR analysis of liver gluconeogenesis markers phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).  Total RNA was isolated 
from liver samples (~100 mg) using TRIzol® reagent (Invitrogen, 1 mL/100 mg sample), 
followed by spin-column purification (RNeasy® kit, Qiagen) and on-column DNAse treatment 
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(Qiagen) according to the manufacturer’s instructions.  RNA concentrations were determined by 
UV spectrophotometry (NanoDrop).  One microgram of total RNA was used for reverse 
transcription with oligo(dT) primers (SuperScript® III First-Strand Synthesis SuperMix, Life 
Technologies) according to the manufacturer’s instructions.  Quantitative PCR reactions 
included 1 µL of cDNA diluted 1:100, 0.4 µM primers, 2x SYBR Green PCR Master Mix 
(Invitrogen) in 25 µL total volume, and were read out by a CFX96™ Real-Time PCR Detection 
System (BioRad).  Transcript levels were determined using two known primer pairs26,27 for each 
gene of interest (Supplementary Table S4), which were normalized against tubulin and beta-
actin transcripts (ΔΔCT method), and expressed relative to the lowest sample.  Duplicate control 
assays without reverse transcriptase treatment were run for each RNA preparation and primer 
set used.  Statistics were performed using a two-tail Student’s t-test, and significance levels 
shown in the figures are * p < 0.05 versus vehicle control group or ** p < 0.01 versus vehicle 
control group. 
 
Amyloid peptide measurements.  Lean C57BL/6J mice were treated with 6bK (80 
mg/kg), vehicle alone, or bisepi-6bK (80 mg/kg).  Two hours post-injection, hemibrains were 
promptly dissected after CO2-euthanasia and stored at -80 °C until extraction.  A hemibrain 
(~150 mg wet weight) was homogenized in a Dounce homogenizer in 0.2% diethylamine and 50 
mM NaCl (900 µL).  The homogenate was centrifuged at 20,000 × g for 1 h at 4°C to remove 
insoluble material.  A fraction of supernatant (100 µL) was neutralized with 1:10 volume of Tris 
HCl, pH 6.8. The sample was diluted 1:4 in assay buffer, and analyzed for Aβ(40) and Aβ(42) 
levels using the respective Aβ ELISA assays (Invitrogen) following the manufacturer’s protocols. 
3.12 References 
1 Drag, M. & Salvesen, G. S. Emerging principles in protease-based drug discovery. Nat 
Rev Drug Discov 9, 690-701, doi:nrd3053 [pii]10.1038/nrd3053 (2010). 
84 
 
2 Drucker, D. J. The biology of incretin hormones. Cell Metab 3, 153-165, doi:S1550-
4131(06)00028-3 [pii]10.1016/j.cmet.2006.01.004 (2006). 
3 Duckworth, W. C., Bennett, R. G. & Hamel, F. G. Insulin degradation: progress and 
potential. Endocr Rev 19, 608-624 (1998). 
4 Mirsky, I. A. & Broh-Kahn, R. H. The inactivation of insulin by tissue extracts; the 
distribution and properties of insulin inactivating extracts. Arch Biochem 20, 1-9 (1949). 
5 Karamohamed, S. et al. Polymorphisms in the insulin-degrading enzyme gene are 
associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. 
Diabetes 52, 1562-1567 (2003). 
6 Gu, H. F. et al. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene 
contribute to variation in plasma insulin levels. Diabetes 53, 2137-2142 (2004). 
7 Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 
diabetes. Nature 445, 881-885, doi:10.1038/nature05616 (2007). 
8 Zeggini, E. et al. Replication of genome-wide association signals in UK samples reveals 
risk loci for type 2 diabetes. Science 316, 1336-1341, doi:10.1126/science.1142364 
(2007). 
9 Bartl, J. et al. Disorder-specific effects of polymorphisms at opposing ends of the Insulin 
Degrading Enzyme gene. BMC medical genetics 12, 151, doi:10.1186/1471-2350-12-
151 (2011). 
10 Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-
protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl 
Acad Sci U S A 100, 4162-4167, doi:10.1073/pnas.0230450100 [pii] (2003). 
11 Abdul-Hay, S. O. et al. Deletion of insulin-degrading enzyme elicits antipodal, age-
dependent effects on glucose and insulin tolerance. PLoS One 6, e20818, 
doi:10.1371/journal.pone.0020818 (2011). 
85 
 
12 Leissring, M. A. et al. Designed inhibitors of insulin-degrading enzyme regulate the 
catabolism and activity of insulin. PLoS One 5, e10504, 
doi:10.1371/journal.pone.0010504 (2010). 
13 Abdul-Hay, S. O. et al. Optimization of peptide hydroxamate inhibitors of insulin-
degrading enzyme reveals marked substrate-selectivity. J Med Chem 56, 2246-2255, 
doi:10.1021/jm301280p (2013). 
14 Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B. F. Activity-based 
probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A 101, 
10000-10005, doi:10.1073/pnas.0402784101 (2004). 
15 Knight, Z. A. & Shokat, K. M. Chemical genetics: where genetics and pharmacology 
meet. Cell 128, 425-430, doi:10.1016/j.cell.2007.01.021 (2007). 
16 Workman, P. & Collins, I. Probing the probes: fitness factors for small molecule tools. 
Chem Biol 17, 561-577, doi:10.1016/j.chembiol.2010.05.013 (2010). 
17 Gartner, Z. J. et al. DNA-templated organic synthesis and selection of a library of 
macrocycles. Science 305, 1601-1605, doi:10.1126/science.1102629 [pii] (2004). 
18 Tse, B. N., Snyder, T. M., Shen, Y. & Liu, D. R. Translation of DNA into a library of 
13,000 synthetic small-molecule macrocycles suitable for in vitro selection. J Am Chem 
Soc 130, 15611-15626, doi:10.1021/ja805649f (2008). 
19 Kleiner, R. E., Dumelin, C. E., Tiu, G. C., Sakurai, K. & Liu, D. R. In vitro selection of a 
DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. J 
Am Chem Soc 132, 11779-11791, doi:10.1021/ja104903x (2010). 
20 Georghiou, G., Kleiner, R. E., Pulkoski-Gross, M., Liu, D. R. & Seeliger, M. A. 
Development and structure-based mechanism of highly specific macrocyclic Src kinase 
inhibitors from a DNA-template library. submitted (2011). 
86 
 
21 Kim, Y. G., Lone, A. M., Nolte, W. M. & Saghatelian, A. Peptidomics approach to 
elucidate the proteolytic regulation of bioactive peptides. Proc Natl Acad Sci U S A 109, 
8523-8527, doi:10.1073/pnas.1203195109 (2012). 
22 Malito, E. et al. Molecular Bases for the Recognition of Short Peptide Substrates and 
Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme†. Biochemistry 47, 
12822-12834, doi:10.1021/bi801192h (2008). 
23 Malito, E., Hulse, R. E. & Tang, W. J. Amyloid beta-degrading cryptidases: insulin 
degrading enzyme, presequence peptidase, and neprilysin. Cellular and molecular life 
sciences : CMLS 65, 2574-2585, doi:10.1007/s00018-008-8112-4 (2008). 
24 Shen, Y., Joachimiak, A., Rosner, M. R. & Tang, W. J. Structures of human insulin-
degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870-874, 
doi:10.1038/nature05143 (2006). 
25 Guo, Q., Manolopoulou, M., Bian, Y., Schilling, A. B. & Tang, W. J. Molecular basis for 
the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-
degrading enzyme. J Mol Biol 395, 430-443, doi:10.1016/j.jmb.2009.10.072 (2010). 
26 Manolopoulou, M., Guo, Q., Malito, E., Schilling, A. B. & Tang, W. J. Molecular basis of 
catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-
degrading enzyme. J Biol Chem 284, 14177-14188, doi:10.1074/jbc.M900068200 
(2009). 
27 Stella, V. J. & He, Q. Cyclodextrins. Toxicologic pathology 36, 30-42, 
doi:10.1177/0192623307310945 (2008). 
28 Andrikopoulos, S., Blair, A. R., Deluca, N., Fam, B. C. & Proietto, J. Evaluating the 
glucose tolerance test in mice. American journal of physiology. Endocrinology and 
metabolism 295, E1323-1332, doi:10.1152/ajpendo.90617.2008 (2008). 
29 Monzillo, L. U. & Hamdy, O. Evaluation of insulin sensitivity in clinical practice and in 
research settings. Nutrition reviews 61, 397-412 (2003). 
87 
 
30 Mirsky, I. A. & Perisutti, G. Effect of insulinase-inhibitor on hypoglycemic action of 
insulin. Science 122, 559-560 (1955). 
31 Ahren, B., Winzell, M. S. & Pacini, G. The augmenting effect on insulin secretion by oral 
versus intravenous glucose is exaggerated by high-fat diet in mice. The Journal of 
endocrinology 197, 181-187, doi:10.1677/JOE-07-0460 (2008). 
32 Winzell, M. S. & Ahren, B. The high-fat diet-fed mouse: a model for studying 
mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 
53 Suppl 3, S215-219 (2004). 
33 Riddle, M. C. & Drucker, D. J. Emerging therapies mimicking the effects of amylin and 
glucagon-like peptide 1. Diabetes Care 29, 435-449 (2006). 
34 Mooradian, A. D. & Thurman, J. E. Drug therapy of postprandial hyperglycaemia. Drugs 
57, 19-29 (1999). 
35 Malaisse, W. J. Pharmacology of the meglitinide analogs: new treatment options for type 
2 diabetes mellitus. Treatments in endocrinology 2, 401-414 (2003). 
36 Hollander, P. et al. Effect of pramlintide on weight in overweight and obese insulin-
treated type 2 diabetes patients. Obesity research 12, 661-668, doi:10.1038/oby.2004.76 
(2004). 
37 Duckworth, W. C. & Kitabchi, A. E. Insulin and glucagon degradation by the same 
enzyme. Diabetes 23, 536-543 (1974). 
38 Shroyer, L. A. & Varandani, P. T. Purification and characterization of a rat liver cytosol 
neutral thiol peptidase that degrades glucagon, insulin, and isolated insulin A and B 
chains. Archives of biochemistry and biophysics 236, 205-219 (1985). 
39 Bennett, R. G., Duckworth, W. C. & Hamel, F. G. Degradation of amylin by insulin-
degrading enzyme. J Biol Chem 275, 36621-36625, doi:10.1074/jbc.M006170200 
(2000). 
88 
 
40 Authier, F., Mort, J. S., Bell, A. W., Posner, B. I. & Bergeron, J. J. Proteolysis of 
glucagon within hepatic endosomes by membrane-associated cathepsins B and D. J 
Biol Chem 270, 15798-15807 (1995). 
41 Fontes, G. et al. Miniglucagon (MG)-generating endopeptidase, which processes 
glucagon into MG, is composed of N-arginine dibasic convertase and aminopeptidase B. 
Endocrinology 146, 702-712, doi:10.1210/en.2004-0853 (2005). 
42 Trebbien, R. et al. Neutral endopeptidase 24.11 is important for the degradation of both 
endogenous and exogenous glucagon in anesthetized pigs. American journal of 
physiology. Endocrinology and metabolism 287, E431-438, 
doi:10.1152/ajpendo.00353.2003 (2004). 
43 Young, A. Effects on plasma glucose and lactate. Adv Pharmacol 52, 193-208, 
doi:10.1016/S1054-3589(05)52010-6 (2005). 
44 Gelling, R. W. et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell 
hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100, 1438-
1443, doi:10.1073/pnas.0237106100 (2003). 
45 Kolterman, O. G., Gottlieb, A., Moyses, C. & Colburn, W. Reduction of postprandial 
hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin 
analogue. Diabetes Care 18, 1179-1182 (1995). 
46 Riediger, T., Zuend, D., Becskei, C. & Lutz, T. A. The anorectic hormone amylin 
contributes to feeding-related changes of neuronal activity in key structures of the gut-
brain axis. American journal of physiology. Regulatory, integrative and comparative 
physiology 286, R114-122, doi:10.1152/ajpregu.00333.2003 (2004). 
47 Young, A. Inhibition of glucagon secretion. Adv Pharmacol 52, 151-171, 
doi:10.1016/S1054-3589(05)52008-8 (2005). 
48 Schmitz, O., Brock, B. & Rungby, J. Amylin agonists: a novel approach in the treatment 
of diabetes. Diabetes 53 Suppl 3, S233-238 (2004). 
89 
 
49 Crowell, M. D., Mathis, C., Schettler, V. A., Yunus, T. & Lacy, B. E. The effects of 
tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes 
mellitus. Neurogastroenterology and motility : the official journal of the European 
Gastrointestinal Motility Society 17, 738-743, doi:10.1111/j.1365-2982.2005.00681.x 
(2005). 
50 Gedulin, B. R., Jodka, C. M., Herrmann, K. & Young, A. A. Role of endogenous amylin in 
glucagon secretion and gastric emptying in rats demonstrated with the selective 
antagonist, AC187. Regulatory peptides 137, 121-127, 
doi:10.1016/j.regpep.2006.06.004 (2006). 
51 Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a 
pathophysiologic and therapeutic makeover. The Journal of clinical investigation 122, 4-
12, doi:10.1172/JCI60016 (2012). 
52 Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the 
treatment of obesity and T2DM. Nature reviews. Endocrinology, 
doi:10.1038/nrendo.2013.47 (2013). 
 
 
  
90 
 
Appendix 1 
Metabolomics Experiments to identify E.Coli derived ligand of MR1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Appendix is adapted from: 
 
Jacinto, L et al. MAIT Recognition of a Stimulatory Bacterial Antigen Bound to MR1. The Journal 
of Immunology. 2013 
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A1.1 Introduction 
MR1-restricted Mucosal Associated Invariant T (MAIT) cells represent a sub-population 
of αβ T cells with innate-like properties and limited TCR diversity. MAIT cells are of interest due 
to their reactivity against bacterial and yeast species, suggesting they play a role in defense 
against pathogenic microbes. Despite the advances in understanding MAIT cell biology, the 
molecular and structural basis behind their ability to detect MR1-antigen complexes is unclear. 
Here we present our structural and biochemical characterization of MAIT TCR engagement of 
MR1 presenting an E. coli-derived stimulatory ligand, rRL-6-CH2OH previously found in 
Salmonella typhimurium. We show a clear enhancement of MAIT TCR binding to MR1 due to 
presentation of this ligand. Our structure of a MAIT TCR/MR1/rRL-6-CH2OH complex shows an 
evolutionarily conserved binding orientation, with a clear role for both the CDR3α and CDR3β 
loops in recognition of the rRL-6-CH2OH stimulatory ligand. We also present two additional 
xeno-reactive MAIT TCR/MR1 complexes that recapitulate the docking orientation documented 
previously despite having variation in the CDR2β and CDR3β loop sequences. Our data 
supports a model by which MAIT TCRs engage MR1 in a conserved fashion, their binding 
affinities modulated by the nature of the MR1 presented antigen or diversity introduced by 
alternate Vβ usage or CDR3β sequences. 
 
A1.2 Results 
These results prompted us to analyze by mass spectrometry the content of the hbMR1 
in both E. coli exposed and non-exposed protein samples. Normal Phase QTOF analysis clearly 
identified a compound with a retention time of ~ 7 minutes present only in the E. coli treated 
sample (Figure 2A). Mass spectrometry analysis of this compound determined a compound with 
a m/z ratio of 329.1095 and whose fragmentation yielded a pattern nearly identical to that found 
for rRL-6-CH2OH (r-RL) (Figure 2B), a MAIT cell stimulatory ligand characterized from 
Salmonella typhimurium supernatant10. This compound is generated as a by-product of the 
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riboflavin synthesis pathway and its structure comprises a lumazine core and a ribityl chain 
(Figure 2A, inset). rRL-6-CH2OH has been shown to trigger MAIT cell activation in a MR1 
dependent manner, and displayed the strongest potency in activating MAIT cells among three 
structurally related compounds10. Thus, the increased MAIT TCR affinity to the E. coli-treated 
hbMR1 sample correlates with the presence of this ribityl moiety, which our model suggested9 
directly participates in MAIT TCR recognition of MR1 presented antigen. 
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Figure A1.1 MAIT Recognition of a Stimulatory Bacterial Antigen Bound to MR1. MS 
reveals the presence of rRL-6-CH2OH in the E. coli–treated hbMR1 sample. (A) Extracted ion 
chromatograms (EICs) for rRL-6-CH2-OH (m/z 329.1103) from hbMR1 protein exposed to E. coli 
(lower panel) compared with untreated protein control (upper panel). EIC shows compound with 
m/z 329.1103 present only in E. coli–treated sample (inset). (B) Compound with m/z 329.1095 
(left peak, upper panel) from the E. coli–treated hbMR1 sample and product ions from targeted 
fragmentation (lower panel); the structures of each of the products of the fragmentation are 
shown as insets. The precursor ion is indicated by a diamond. Tandem mass spectrometry 
(MS/MS) product ion data match against the theoretical fragmentation pattern of rRL-6-CH2OH 
(right peak, upper panel) within <5 ppm. 
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A1.3 Methods 
Mass spectrometry analysis of hbMR1. 6.25 µg of DMRL (m/z 325.1154) was injected 
onto a Luna NH2 4.6x50 mm, 5 µm column. The flow was analyzed by ESI-TOF-MS on a 
Bruker maXis impact QTOF with Agilent 1290 HPLC using a binary gradient of 95% B to 0% 
over 5 minutes (A: 20 mM ammonium acetate in water, pH 9.0; B: Acetonitrile). Target ion 
detected after elution with aqueous gradient; data was collected in negative ion mode. Retention 
time was obtained by extracted ion chromatogram of respective m/z; product ions were obtained 
by tandem MS with a collision energy of 20eV. For hbMR1, comparison of hbMR1 protein that 
was exposed to E. coli sn and an untreated control hbMR1 sample were analyzed on a Bruker 
maXis impact QTOF LC/MS in negative ion mode. 5 uL each of 25 µM hbMR1 was injected onto 
a Luna NH2 4.6x50 mm, 5 um column in 20 mM ammonium acetate, pH 9 buffer and eluted with 
an aqueous gradient as described above. Retention time of rRL-6-CH2OH was determined by 
extracted ion chromatograms using the m/z values. Product ions were obtained from target 
fragmentation at collision induced voltages of 20.  
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
Appendix 2 Evaluation of Potent α/β -Peptide Analogue of GLP-1 with 
Prolonged Action In Vivo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from prepared manuscript: 
 
Johnson, LM et al. Proteolysis in the Context of Diabetes:  Evaluation of  Potent α/β-Peptide 
Analogue of GLP-1 with Prolonged Action In Vivo. 2014 
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A2.1 Introduction 
Glucagon-like peptide-1 (GLP-1) is the natural agonist for GLP-1R, a G protein-coupled 
receptor (GPCR) that is displayed on the surface of pancreatic β cells.  Activation of GLP-1R 
augments glucose-dependent insulin release from β cells and promotes β cell survival.  These 
properties are attractive for treatment of type 2 diabetes, but GLP-1 is rapidly degraded by 
peptidases in vivo.  Efforts to develop small-molecule agonists of GLP-1R have not been 
successful, presumably because receptor activation requires contact over an extended surface.  
All potent GLP-1R agonists reported to date are comprised exclusively of α-amino acid 
residues, with prolonged in vivo activity achieved by variations in sequence, incorporation of 
stabilizing appendages, and/or specialized delivery strategies.  We describe an alternative 
design strategy for retaining GLP-1-like function but engendering prolonged activity in vivo, 
based on strategic replacement of native α residues with conformationally constrained β-amino 
acid residues.  This approach may be generally useful for developing stabilized analogues of 
peptide hormones. As part of this collaboration, with the Gellman laboratory at University of 
Wisconsin, Madison, I ran comparative glucose tolerance tests in mice to assay the efficacy of 
different GLP-1 analogues. 
 
A2.2 Results  
 The ability of α/β -peptide 6 to augment insulin secretion from mouse pancreatic islets in 
response to elevated glucose led us to evaluate the activity of this GLP-1 analogue in vivo via 
glucose tolerance tests (GTT) (Figure 3). In addition to the α/β -peptide and GLP-1(7-37)-NH2, 
these studies included exendin-4 (39 residues), all three of which were tested for the ability to 
normalize circulating glucose levels. GLP-1, exendin-4 and α/β -peptide 6  were compared at a 
dose of 1 mg/kg, and descending doses were examined for the α/β -peptide.  For mice injected 
with vehicle rather than peptide (negative control), the intraperitoneal glucose challenge causes 
a rapid rise in blood glucose concentration that subsides after 30 min (Figure 3A-B). Mice 
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injected with GLP-1, exendin-4 or α/β -peptide 6 at 1 mg/kg showed a dramatic suppression in 
the rise of glucose relative to vehicle-treated mice during the GTT; the three compounds were 
equally effective at this dose.  Dose-response behavior was observed for 6, with glucose control 
maintained at 0.1 mg/kg, but not at 0.01 mg/kg.   
 In order to determine whether the GLP-1R agonists display prolonged action, I repeated 
the GTT 5 hr after agonist administration (Figure 3C).  Mice treated with GLP-1(7-37)-NH2 
showed no significant difference from those treated with vehicle 30 min after the second glucose 
challenge; this result is expected based on the rapid enzymatic inactivation of GLP-1 in vivo.  In 
contrast, the glucose-lowering effect of exendin-4 is maintained at 5 hr, which is consistent with 
prior observations.  Exendin-4 persists longer in the bloodstream than does GLP-1 because 
exendin-4 is not cleaved by DPP-4 and is only very slowly degraded by neprilysin or other 
peptidases.12,13 α/β -Peptide 6 exerted the same glucose-lowering effect at 5 hr as exendin-4 
(each at 1 mg/kg).  The ability of 6 to induce control of blood glucose levels at 5 hr was 
manifested even when the α/β -peptide was administered at 0.1 mg/ml.  These results 
presumably reflect the resistance of this α/β -peptide to degradation by either DPP-4 or 
neprilysin.  
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Figure A2.1 α/β-peptide 6 demonstrates long lasting improvement of in vivo glucose 
tolerance.  
A) Plasma glucose values during a glucose tolerance test (GTT) for mice treated with GLP-1(7-
37)-NH2 (1 mg/kg), Exendin-4 (Ex-4, 1 mg/kg), varying doses (0.01-1 mg/kg) of α/β-peptide 6 or 
vehicle. Upward arrow indicates timing of the peptide treatments delivered via IP injection. 
Results show mean (± SEM) of 4 separate mice per condition. B) Average area under the curve 
(AUC) values for the GTT data shown in A. C) Plasma glucose values at 30 mins following a 
second GTT that was conducted 5 hr following that shown in A. *, P < 0.05 vs. vehicle. 
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A2.3 Discussion  
Our results show that a GLP-1- -
amino acid residues with conformationally constrained β-amino acid residues can maintain 
native-like agonist activity at the GLP-1 receptor.  α/β -Peptide 6 mimics GLP-1 in terms of 
augmenting glucose-stimulated insulin secretion from pancreatic β cells and regulating blood 
glucose levels in vivo.  The prolonged effect of this α/β -peptide relative to GLP-1 is attributed to 
the strongly diminished susceptibility to degradation by widely distributed peptidases, a property 
that arises in part from the multiple β residue replacements.  The favorable characteristics 
displayed by α/β -peptide 6 in vitro and in vivo suggest that backbone-modification strategies 
involving periodic replacement of α residues with β residues may prove to be generally useful 
for developing potent and highly stable analogues of peptide hormones and other signaling 
peptides for which the receptor-bound conformation is at least partially α-helical.  Side chain 
cross-links have been widely employed for this purpose in the past,17-29 but recent structural 
studies have revealed that the large additional molecular surfaces generated by the cross-link 
itself can make intimate contacts with partner protein surfaces.44-46  Such contacts might alter 
binding affinity and/or selectivity relative to the natural prototype.  Periodic α-to-β replacement 
may represent a more effective approach to retaining an α-helix-like shape47 and the binding 
selectivity of a prototype α-peptide while diminishing susceptibility to proteolytic action.   
 
A2.4 Method 
Glucose Tolerance Test (GTT). GLP-1(7-37)-NH2, exendin-4 or α/β-peptide 6 was 
administered to mice by interperitoneal (i.p.) injection at a 1 mg/kg dose, or lower for α/β-peptide 
6, using an injection volume of 10 mL/kg body mass.  Each peptide was first dissolved in 
prefiltered DMSO at 10 mg/mL concentration, then diluted >20-fold with TBS buffer, pH 7.4 
(final DMSO conc. = <5%). Glucose was administered by i.p. injection with a sterile-filtered 30% 
D-glucose-saline solution at a 1.5 g/kg dose using a 5 mL/kg injection volume.  
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Thirteen-week-old male C57BL/6J mice (n = 4) were fasted overnight on wood chip 
bedding for 15 hours prior to the experiment. Blood glucose levels were monitored from a tail tip 
bleed using an ACCU-CHEK Aviva blood glucose meter.  Fasting glucose levels were 
measured at 75 minutes prior to the glucose injection (t = -75 min), and the compound injection 
was performed 60 minutes prior to the glucose injection (t = -60 min). Glucose levels were 
measured immediately prior to the glucose injection (t = 0 min) to assess any changes in the 
baseline glucose caused by peptide administration. Blood glucose levels were monitored at 30, 
60, 90, and 120 minutes after injection of glucose.  
Five hours after peptide injection, the mice received a second injection of 1.5 g/kg 
glucose.  Blood glucose was monitored at 30 min after this second glucose injection.  Mice were 
sacrificed by CO2 inhalation at the conclusion of the GTT. 
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Figure A3.1 Inhibitor Selection Scheme a, Overview of the in vitro selection of a 13,824-
membered DNA-templated macrocycle library for IDE binding affinity18,19.  b, Enrichment results 
from two independent in vitro selections against N-His6-mIDE using the DNA-templated 
macrocycle library18. The numbers highlight compounds enriched at least 2-fold in both 
selections. c, Structures of IDE-binding macrocycles 1-6 decoded from DNA library barcodes 
corresponding to building blocks A, B, C and D.  The cis and trans isomers are labeled ‘a’ and 
‘b’, respectively.  The two isomers were synthesized as previously reported18,19 and separated 
by HPLC.  IDE inhibition activity was assayed by following cleavage of the fluorogenic peptide 
substrate Mca-RPPGFSAFK(Dnp)-OH.  
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Figure A3.2 Inhibition of human and mouse IDE activity demonstrated using distinct 
assays.  a and b, cleavage of the fluorogenic substrate peptide Mca-RPPGFSAFK(Dnp)-OH by 
human and mouse IDE in the presence of inhibitors (a) 6b and (b) 6bK.  c, Homogeneous time-
resolved fluorescence (HTRF, Cisbio) assay measuring degradation of insulin by IDE (R&D) in 
the presence of 6b, 6bK and 28.  d, LC-MS assay for ex vivo degradation of CGRP (10 µM) by 
endogenous IDE in mouse plasma in the presence of 6b. e and f, Biochemical assays 
suggesting that 6b binds a site in IDE distinct from the conventional peptide substrate binding 
site known to bind substrate mimetic Ii1.  Yonetani–Theorell double inhibitor plots of IDE activity 
in the presence of (e) 6b and Ii1, or (f) 6b and bacitracin.  Crossing lines indicate synergistic 
and independent binding of inhibitors, while parallel lines indicate competition for binding to the 
enzyme.  The inhibitors assayed using the fluorogenic substrate Mca-RPPGFSAFK(Dnp)-OH. 
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Figure A3.3 Data collection and refinement statistics (molecular replacement), docking 
simulation for 6b, and competition test between insulin and fluorescein-labeled 
macrocycle 31 for binding CF-IDE.  a, One crystal was used to solve the CF-IDE•6b structure.  
The highest-resolution shell is shown in parentheses.  Structure coordinates are deposited in 
the Protein Data Bank (accession number 4TLE).  b, Molecular docking simulations are 
consistent with the placement of building blocks A and B in the structural model. The structure 
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of 6b in binding site from crystallographic data with composite omit map contoured at 1.0 σ (p-
benzoyl-phenylalanine is shown in red, cyclohexylalanine in blue, and the backbone in purple).  
c, Highest-scoring pose from DOCK simulations (glutamine group is shown in green).  d, 
Residue decomposed energy of the crystal (green) and docked (blue) poses of 6b.  e, 
Competition test between the fluorescein-labeled macrocycle 31 and insulin for binding CF-IDE.  
Cysteine-free catalytically-inactive IDE was titrated against 0.9 nM macrocycle 31 alone () or 
together with 2.15 μM insulin (), producing a shift in apparent dissociation constant for 
macrocycle 31 according to equation Eq. 1 (Supplementary Information). Representative 
fluorescence polarization plots are shown.  
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Figure A3.4 Small molecule-enzyme mutant complementation study to confirm the 
macrocycle binding site and placement of the benzophenone and cyclohexyl building-
block groups.  a, IDE mutant A479L is inhibited by 6b >600-fold less potently compared to 
wild-type IDE.  b, Analog 9, in which the p-benzoyl ring is substituted for a smaller tert-butyl 
group, inhibits A479L IDE and WT IDE comparably.  c, Similarly, IDE mutant G362Q is inhibited 
77-fold less potently by 6b compared with WT IDE.  d, Analog 13, in which the L-cyclohexyl 
alanine side chain was substituted with a smaller L-leucine side chain, inhibits G362Q IDE and 
WT IDE comparably.  The full list of IDE mutants investigated is shown in Supplementary Table 
S5. 
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Figure A3.5 Pharmacokinetic parameters of 6bK.  a, Plasma binding, plasma stability, and 
microsomal stability (1 h incubation) data was provided by Dr. Stephen Johnston and Dr. Carrie 
Mosher (Broad Institute).  b, Heavy 6bK was synthesized with 15N,13C-lysine for stable-isotope 
dilution LC-MS quantitation.  c Concentration of 6bK in mice tissues and plasma collected over 
4 hours (n = 1-2).  d, Average biodistribution of 6bK in five lean mice at 150 min post-injection 
of 6bK 80 mg/kg i.p. at the endpoint of a IPGTT experiment.  We did not detect 6bK in the brain 
even using 10-fold concentrated samples for LC-MS injection compared to other tissues. 
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Figure A3.6 Dose tolerance, augmented insulin hypoglycemic action by 6bK in mice, and 
unaffected amyloid peptide levels in the mouse brain.  a, Body weight measurements for 
C57BL/6J mice treated with 6bK (, 80 mg/kg i.p.) or vehicle alone ().  Mice treated with 6bK 
(, 80 mg/kg) are active, display normal posture, normal grooming, and response to stimulation.  
b, Increased hypoglycemic response to a high dose of insulin (1.0 U/kg) under acute IDE 
inhibition (compare with Fig. 4b).  Non-fasted male C57BL/6J mice were treated with a single 
i.p. injection of IDE inhibitor 6bK (, 80 mg/kg) or vehicle alone (), followed by i.p. insulin 
(Humulin-R, 1.0 U/kg). The animals in the 6bK-treated cohort experienced lethargy and 
hypothermia consistent with the augmented effect of insulin.  c and d, Treatment of C57BL/6J 
lean mice with 6bK (, 80 mg/kg, n = 6) does not change brain levels of Aβ(40) or Aβ(42) 
peptides in the brain 2 h post injection compared to treatment with vehicle alone (, n = 5) or 
inactive diastereomer bisepi-6bK (, 80 mg/kg, n = 6).  All data points and error bars represent 
mean ± SEM.   
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Figure A3.7 Dependence of insulin and glucagon secretion on the route of glucose 
administration (oral or i.p.) due to the both the ‘incretin effect’ as well as the 
hyperinsulinemic phenotype of DIO versus lean mice.  a, The early insulin response to 
glucose in lean and DIO mice is higher during OGTT than IPGTT.  b, Suppression of glucagon 
secretion post-glucose administration is less effective after IPGTT and in DIO mice.  All data 
points and error bars represent mean ± SEM.  Statistics were performed using a two-tail 
Student’s t-test, and significance levels shown in the figures are * p < 0.05 or ** p < 0.01 
between the labeled groups. 
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Figure A3.8 Low-potency diastereomers of 6bK used to determine effective dose range of 
2 mg/mouse and confirm on-target IDE inhibition effects during IPGTTs in lean and DIO 
mice.  a, Inhibition of mouse IDE activity by low potency diastereomers of 6bK. The 
stereocenters altered in each compound relative to those of 6bK are labeled with a star. b, The 
effects of 6bK (, 90 mg/kg) were compared to the weakly active stereoisomer epi-C-6bK (, 
90 mg/kg) and vehicle controls () during an ipGTT to determine the dosing range in lean mice. 
c, Two doses of 6bK, 80 mg/kg () and 40 mg/kg () were compared with inactive bisepi-6bK 
(, 80 mg/kg) and vehicle alone (). d and e, Administration of 6bK (, 80 mg/kg) to lean mice 
not followed by injection of a nutrient such as glucose or pyruvate did not significantly alter (d) 
basal blood glucose or (e) basal hormone levels compared to bisepi-6bK () or vehicle controls 
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(). All data points and error bars represent mean ± SEM.  Statistics were performed using a 
two-tail Student’s t-test, and significance levels shown in the figures are * p < 0.05 versus 
vehicle control group; ** p < 0.01 versus vehicle control group.  
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Figure A3.9 Relative area under the curve calculations and 6bK dose response for the 
glucose tolerance tests shown in Fig. 3.3.  a, During OGTT, lean and DIO mice treated with 
6bK (, 2 mg/animal) display improved glucose tolerance (lower blood glucose area), compared 
to vehicle controls () and inactive bisepi-6bK ().  b, In contrast, during IPGTT both lean and 
DIO mice treated with 6bK () display impaired glucose tolerance (higher blood glucose area) 
compared to vehicle () or bisepi-6bK () controls.  c and d, Dose-response of 6bK (40 and 
90 mg/kg; see Fig. 3d for 60 mg/kg) followed by IPGTT in DIO mice.  Vehicle alone () and a 
matching dose of bisepi-6bK () were used as controls.  c, DIO mice treated with low doses of 
6bK (, 40 mg/kg) responded to IPGTT in either of two ways: improved glucose tolerance 
throughout the experiment (n = 3) or a hyperglycemic rebound as described in the main text (n = 
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4), suggesting this dose is too low to achieve a consistent effect (note the large error bars).  d, 
Mice treated with high doses of 6bK (, 90 mg/kg) respond similarly to 60 mg/kg (Fig. 3d), but 
the potential weak activity observed for bisepi-6bK (IC50 > 100 µM) at this high dose () 
compared to vehicle alone () suggests that 90 mg/kg may be too high.  All data points and 
error bars represent mean ± SEM.  Statistics were performed using a two-tail Student’s t-test, 
and significance levels shown in the figures is * p < 0.05 versus vehicle control group.  See the 
Supplementary Methods section for a description of the AUC calculation. 
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Figure A3.10 Oral glucose tolerance of mice lacking IDE compared to WT lean mice, and 
lack of effect of 6bK treatment in IDE–/– knockout mice. a, Mice lacking IDE treated with 6bK 
(, 80 mg/kg, i.p.) followed by oral glucose produce an identical response compared to vehicle-
treated controls () of the same genotype (IDE–/–). b, Transient IDE inhibition in age-matched 
IDE+/+ WT control mice treated with 6bK (, 80 mg/kg, i.p.) display improved oral glucose 
tolerance compared to vehicle-treated controls () of the same genotype (similar to Fig. 3a). c, 
In contrast, when mice lacking IDE (, IDE–/–) are compared with age-matched IDE+/+ controls 
() the IDE knockout mice display impaired oral glucose tolerance, supporting the hypothesis 
that chronic deletion of IDE leads to pronounced compensatory changes in metabolism that are 
not predictive of the outcome of IDE inhibition.10,11  All data points and error bars represent 
mean ± SEM.  Statistics were performed using a two-tail Student’s t-test, and significance level 
shown in the figures is * p < 0.05 versus WT vehicle control group.   
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Supplementary Figure S1. Western blot for IDE using whole blood lysate (0.5 µL/well) from 
IDE–/– mice and a wild-type (WT) control sample. 
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Supplementary Scheme S1. Fmoc-based solid-supported synthesis of 6bK followed by on-
resin macrocyclization. 
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IDE substrates in vitro 
(reference) 
Alternative degrading 
enzymes (Brenda db) 
kcat 
(min
-1
) 
KM 
(µM) 
kcat/ 
KM 
IC50 
(µM) 
X-ray 
struct. 
IDE substrate 
in vivo (ref.) 
insulin 
28,29
 
lysosomal proteases, 
disulfide reductase 
1.52 <0.03 50 
- 2WBY 
KO study 
30,31
 
 2WC0 
Aβ (40, 42) 
32,33
 NEP, cathepsin D 52 1.23 43 - 
2G47 
KO study 
30,34,35
 
2WK3 
calcitonin-gene related 
peptide
 6
 
ECE, PREP - - - - - KO study 
6
 
glucagon 
36,37
 
NEP, nardilysin, DPP-
IV, cathepsins B and C 
38.5 3.46 11 weak 2G49 this study 
amylin 
38
 - n/a 0.3* n/a 0.16 
3HGZ 
this study 
2G48 
TGF-α 
39
 - - 0.15* - 0.08 3E50   - 
IGF-1 
34,40
 DPP-IV - weak - - -  - 
IGF-2 
34,40
 - - 0.1* - 0.06 3E4Z  - 
somatostatin-14 
41
 
nardilysin, dactylysin, 
aminopeptidase B, 
THOP, neurotensin-
degrading enzyme 
22.8 7.5 3.0 - -  - 
bradykinin  
42
 
ACE, aminopeptidase 
P, carboxypeptidase N, 
NEP, DPP-II, DPP-IV, 
- 4.2 -   - 3CWW  - 
kallidin 
42
 
ACE, aminopeptidase 
P, carboxypeptidase N 
- 7.3 - - -  - 
atrial NP (ANP) 
43,44
 NEP - 0.06 - - 3N57  - 
B-type NP  (BNP) 
44
 
NEP, fibroblast 
activation protein-α 
- weak - >1 3N56  - 
relaxin 
45
 - - 0.11* - 0.054 -  - 
relaxin-3 
45
 - - 0.36* - 0.182 -  - 
insulin-like peptide 3 
46
 - 0.15 0.055 2.7 - -  - 
β-endorphin (1-31) 
42
 NEP 21 13 1.6 - -  - 
growth hormone releasing 
factor (1−29) 42 
DPP-IV, NEP 23.4 11.9 2.0 - -  - 
pancreastatin (1-49) 
42
 - 10.6 41.7 0.25 - -  - 
dynorphin  B (1-13) 
42
 NEP 15.1 18.3 0.8 - -  - 
 A (1-17) 
42
 NEP 18.4 37.4 0.5 - -  - 
 B (1-9) 
42
 NEP 10.3 26.8 0.4 - -  - 
 A (1-13) 
42
 NEP 3.74 40.6 0.09 - -  - 
 A (1-10) 
42
 NEP 3.74 39.4 0.09 - -  - 
 A (1-8) 
42
 NEP 0.66 63.5 0.01 - -  - 
 A (1-9) 
42
 NEP 0.33 60.5 0.01 - -  - 
Table A3.1 Literature survey of putative IDE substrates identified using in vitro assays.  
 (*) KM estimated based on IC50 for inhibition of insulin degradation.  Abbreviations: Aβ = amyloid 
beta; TGF-alpha = transforming growth factor-alpha; IGF = insulin-like growth factor; NP = 
natriuretic peptide; GRF = gastrin release factor; NEP = neprilysin; PREP = prolyl 
endopeptidase; ECE = endothelin converting enzyme; THOP = thimet oligopeptidase; ACE = 
angiotensin-converting enzyme; DPP = dipeptidylpeptidase. Known non-substrates of IDE 
include glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), 
epithelial growth factor 1 (EGF-1) and C-peptide. 
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Compound Purity (%) Formula 
[M+H]+ 
expected 
[M+H]+ 
found 
Ion count Δ (ppm) 
1a 87.5 C26H41N7O7 564.3140 564.3135 17505 -0.886 
1b 66.4 C26H41N7O7 564.3140 564.3141 237080 0.177 
2a 84.1 C41H55N9O7 786.4297 786.4290 523007 -0.890 
2b 95.3 C41H55N9O7 786.4297 786.4272 627894 -3.179 
3a 84.3 C46H62N6O8 827.4702 827.4703 111258 0.121 
3b 89.9 C46H62N6O8 827.4702 827.4703 26066 0.121 
4a 93.7 C32H52N6O7 633.3970 633.3975 1344574 0.789 
4b 79.7 C32H52N6O7 633.3970 633.3967 591800 -0.474 
5a 97.1 C41H52N6O7 741.3970 741.3987 517852 2.293 
5b 75.4 C41H52N6O7 741.3970 741.3967 208124 -0.405 
6a 98.3 C40H51N7O8 758.3872 758.3886 875721 1.846 
6b 98.9 C40H51N7O8 758.3872 758.3878 14154 0.791 
7 89.6 C40H53N7O7 744.4079 744.4079 21411 -0.040 
8 94.9 C33H47N7O7 654.3610 654.3606 413032 -0.611 
9 80.1 C37H55N7O7 710.4236 710.4239 180420 0.422 
10 76.9 C39H51N7O7 730.3923 730.3917 644559 -0.821 
11 92.6 C40H45N7O8 752.3402 752.3399 77585 -0.399 
12 96.0 C37H47N7O8 718.3559 718.3550 145796 -1.253 
13 95.7 C37H47N7O9 718.3559 718.3569 24610 1.392 
14 58.2 C34H41N7O8 676.3089 676.3082 400965 -1.035 
15 77.5 C38H48N6O7 701.3657 701.3671 124002 1.996 
16 67.3 C38H48N6O7 701.3657 701.3683 19335 3.707 
17 83.2 C39H50N6O7 715.3814 715.3808 298036 -0.839 
18 92.3 C39H50N6O7 715.3814 715.3832 701250 2.516 
19 37.4 C38H48N6O8 717.3606 717.3586 128261 -2.788 
20 74.5 C37H46N6O7 687.3501 687.3503 135532 0.291 
21 95.6 C40H50N6O9 759.3712 759.3726 13461 1.844 
22 97.9 C40H52N6O8S 777.3640 777.3634 121542 -0.772 
23 88.5 C40H52N6O7Se 807.3144 807.3139 1497 -0.619 
24 52.4 C44H52N6O7 777.3970 777.3981 15952 1.415 
25 63.5 C35H43N5O6 630.3286 630.3282 136628 -0.635 
26 74.4 C40H51N7O8 758.3872 758.3876 119065 0.527 
27 90.9 C39H49N7O8 744.3715 744.3708 210827 -0.940 
29 75.3 C42H55N7O8 786.4185 786.4178 234651 -0.890 
28 94.3 C40H50N6O9 759.3712 759.3705 89863 -0.922 
30 97.5 C54H75N9O11S 1058.5380 1058.5402 23247 2.078 
31 81.6 C65H71N7O15 1190.5081 1190.5063 442 -1.512 
6bK 96.6 C41H55N7O7 758.4236 758.4233 501430 -0.396 
heavy-6bK 96.4 C35
13
C6H55N5
15
N2O7 766.4378 766.4388 227096 1.305 
bisepi-6bK 96.7 C41H55N7O7 758.4236 758.4232 133009 -0.527 
epiA-6bK 96.6 C41H55N7O7 758.4236 758.4258 1320288 2.901 
epiB-6bK 94.9 C41H55N7O7 758.4236 758.4235 216951 -0.132 
epiC-6bK 93.9 C41H55N7O7 758.4236 758.4235 177995 -0.132 
Ii1 94.8 C37H45N9O8 744.3464 744.3474 662 1.343 
 
Table A3.2 HPLC and high-resolution mass spectrometry analysis of IDE inhibitor 
analogs. 
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Mutation Primers (forward, reverse) 
A198Q ACATGAGAAGAATGTGATGAATGA-dU-CAGTGGAGAC 
ATCATTCATCACATTCTTCTCATG-dU-TCTG 
A198T AGACTCTTTCAATTGGAAAAAGC-dU-ACAGGG 
AGCTTTTTCCAATTGAAAGAGTC-dU-CCAGGTATCATTCATCACATTCTTCTCATGTTC 
A198C AGACTCTTTCAATTGGAAAAAGC-dU-ACAGGG 
AGCTTTTTCCAATTGAAAGAGTC-dU-CCAGCAATCATTCATCACATTCTTCTCATGTTC 
A198Y ACATGAGAAGAATGTGATGAATGA-dU-TACTGGAGAC 
ATCATTCATCACATTCTTCTCATG-dU-TCTG 
W199L ACATGAGAAGAATGTGATGAATGA-dU-GCCTTAAGACTC  
ATCATTCATCACATTCTTCTCATG-dU-TCTG 
W199F AGACTCTTTCAATTGGAAAAAGC-dU-ACAGGG 
AGCTTTTTCCAATTGAAAGAGTC-dU-GAAGGCATCATTCATCACATTCTTCTC 
W199Y AGACTCTTTCAATTGGAAAAAGC-dU-ACAGGG 
AGCTTTTTCCAATTGAAAGAGTC-dU-ATAGGCATCATTCATCACATTCTTCTC 
F202L ACATGAGAAGAATGTGATGAATGA-dU-GCCTGGAGACTCTTGCAATTG 
ATCATTCATCACATTCTTCTCATG-dU-TCTG 
F202R AGACTCTTTCAATTGGAAAAAGC-dU-ACAGGG 
ATGAATGATGCCTGGAGAC-dU-CCGTCAATTGGAAAAAGCTACAGGG 
I310R ACCCATTAAAGATCGTAGGAATC-dU-CTATGTGACATTTCCCATAC 
AGATTCCTACGATCTTTAATGGG-dU-ACTATTTTGTAAAGTTGTTTAAG 
Y314F ACCCATTAAAGATATTAGGAATCTC-dU-TCGTGACATTTCCCATACCTGACCTTC 
AGAGATTCCTAATATCTTTAATGGG-dU-ACTATTTTG 
V360Q AAAGGGCTGGGTTAATACTCT-dU-CAGGGTGGGCAG 
AAGAGTATTAACCCAGCCCTT-dU-GACTTAAG 
V360R AAAGGGCTGGGTTAATACTCT-dU-AGGGGTGGGCAGAAGGAAGGAGC 
AAGAGTATTAACCCAGCCCTT-dU-GACTTAAG 
G361Q AAAGGGCTGGGTTAATACTCT-dU-GTTCAGGGGCAGAAGGAAGGAGCCC 
AAGAGTATTAACCCAGCCCTT-dU-GACTTAAG 
G362Q AAAGGGCTGGGTTAATACTCT-dU-GTTGGTCAGCAGAAGGAAGGAGCCCGAG 
AAGAGTATTAACCCAGCCCTT-dU-GACTTAAG 
K364A AAGGAGCCCGAGGTTTTA-dU-GTTTTTTATC 
ATAAAACCTCGGGCTCCT-dU-CCGCCTGCCCACCAACAAGAGTATT 
I374M ATGTTTTTTATCATGAATGTGGACT-dU-GACCG 
AAGTCCACATTCATGATAAAAAACA-dU-AAAACCTC 
I374Q ATGTTTTTTATCCAGAATGTGGACT-dU-GACCGAGGAAGG 
AAGTCCACATTCTGGATAAAAAACA-dU-AAAACCTCGGGCTCC 
A479L ATGTCCGGGTTCTGATAGTTTCTAAA-dU-CTTTTGAAGGAAAAACTG 
ATTTAGAAACTATCAGAACCCGGACA-dU-TTTCTGGTCTGAG 
Table A3.3 Site-directed mutagenesis primers. 
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Sequencing primers 
Seq_Fw1 GATTAACTTTATTATTAAAAATTAAAGAGG 
Seq_Re1  CAACATGTAATAATCCTTCCTCGGTC 
Seq_Fw2 GCATGAAGGTCCTGGAAGTCTG 
Seq_Re2 AGGAAGGGTTACATCATCCAGAGC 
Seq_Fw3  
CCATGTACTACCTCCGCTTGC 
Seq_Re3  GCAGATCTCGAGCTCGGATC 
Seq_Fw4 GCTTATGTGGACCCCTTGCACTG 
RT-PCR primers
26,27
 
PEPCK_1_Fw GAACTGACAGACTCGCCCTATGT 
PEPCK_1_Re GTTGCAGGCCCAGTTGTTG 
G6Pase_1_Fw GTGCAGCTGAACGTCTGTCTGT 
G6Pase_1_Re TCCGGAGGCTGGCATTGT 
PEPCK_2_Fw GGTGTTTACTGGGAAGGCATC 
PEPCK_2_Re CAATAATGGGGCACTGGCTG 
G6Pase_2_Fw CATGGGCGCAGCAGGTGTATACT 
G6Pase_2_Re CAAGGTAGATCCGGGACAGACAG 
Tubulin_Fw 
CCTGCTCATCAGCAAGATCC 
Tubulin_Re 
TCTCATCCGTGTTCTCAACC 
Beta-actin_ Fw 
CATCCGTAAAGACCTCTATGCCAAC 
Beta-actin_Re 
ATGGAGCCACCGATCCACA 
Table A3.4 Sequencing and RT-PCR primers. 
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Protein Batch 
Relative 
activity 
Ii1 IC50 
shift * 
6b IC50 
shift 
13 IC50 
shift 
9 IC50 
shift 
Prediction 
hIDE WT 1 1.0 1.0 1.0 1.0 1.0  
hIDE WT 2 1.0 1.0 1.0 1.0 -  
hIDE WT 3 1.0 1.0 1.0 1.0 -  
A198Q 1 1.4 1.0 2.3 - -  
A198T 2 1.5 1.0 16 13.6 - scaffold interaction 
A198Y 2 2.3 1.1 0.5 - -  
W199F 2 1.3 1.8 3.0 3.2 - modest interaction 
W199Y 2 0.3 1.4 1.8 - -  
F202L 1 0.7 1.7 1.7 2.3 -  
F202R 2 0.9 1.1 3.7 4.1 - modest interaction 
I310R 2 3.0 1.9 0.8 0.7 -  
Y314F 2 3.5 1.0 1.2 - -  
V360Q 1 2.6 0.9 1.5 - -  
V360R 3 0.4 0.9 1.4 - -  
G361Q 3 0.7 0.9 0.8 - -  
G362Q 3 1.2 0.6 77 1.8 - cyclohexyl ring interaction 
K364A 2 4.3 1.0 26 10.0 - scaffold interaction 
I374M 1 4.3 1.0 0.7 - -  
A479L 1 0.5 0.9 >600 - 1.0 p-benzoyl interaction 
Table A3.5 Site-directed IDE mutants used in the small molecule-enzyme mutant 
complementation studies. * NB: Ii1 is not known to interact with any of these residues.  
Significant changes in IC50 for Ii1 were presumed to indicate misfolding or other non-inhibitor-
specific protein structure changes.  For example, W199L displayed an IC50 shift of 21-fold for Ii1, 
13-fold for 6b, and 17-fold for analog 13. 
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